

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

New Onset of Diabetes in Association with pancreatic cancer (NODES trial): Protocol of a Prospective, Multicentre Observational trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037267
Article Type:	Protocol
Date Submitted by the Author:	29-Jan-2020
Complete List of Authors:	<p>Illés, Dóra; University of Szeged Faculty of Medicine, First Department of Medicine Ivány, Emese ; University of Szeged Faculty of Medicine, First Department of Medicine Holzinger, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Kosár, Klára; University of Szeged Faculty of Medicine, First Department of Medicine Volosinovszki, Hajnalka; University of Szeged Faculty of Medicine, First Department of Medicine Gordian, Adam M.; Metanomics Health GmbH Kamlage, Beate; Metanomics Health GmbH Zsóri, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Tajti, Máté; University of Szeged Faculty of Medicine, First Department of Medicine Svébis, Márk ; Semmelweis University of Medicine, 1. Department of Internal Medicine Horváth, Viktor; Semmelweis University of Medicine, 1. Department of Internal Medicine Oláh, Ilona; Ilona Tóth Outpatient Clinic Márta, Katalin; Institute for Translational Medicine, University of Pécs Medical School, ; János Szentágothai Research Center, University of Pécs, Antal, Judit; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Zádori, Noémi; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Szentesi, Andrea; Pecs Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group Hegyi, Péter; Pecs Tudományegyetem Általános Orvostudományi Kar, Institution for Translational Medicine Czakó, László; University of Szeged, First Department of Medicine</p>
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Pancreatic disease < GASTROENTEROLOGY, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 ***New Onset of DiabetEs in aSsociacion with pancreatic cancer (NODES trial): Protocol of a***
7 ***Prospective, Multicentre Observational trial***
8
9
10
11
12

13 Dóra Illés¹, Emese Ivány¹, Gábor Holzinger¹, Klára Kosár¹, Hajnalka Volosinovszki¹, M. Gordian Adam²,
14 Beate Kamlage², Gábor Zsóri¹, Máté Tajti¹, Márk Svébis³, Viktor Horváth³, Ilona Oláh⁴, Katalin Márta⁵,
15 Judit Antal⁵, Noémi Zádori⁵, Andrea Szentesi⁶, Péter Hegyi^{5,6}, László Czakó¹
16
17
18
19
20
21
22
23
24
25
26

27 ¹First Department of Medicine University of Szeged, Szeged, HU

28 ²Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany

29 ³ First Department of Medicine University of Semmelweis, Budapest, HU

30 ⁴Ilona Tóth Outpatient Clinic, Diabetes Care, Budapest, HU

31 ⁵Insitute for Translational Medicine, Medical School, University of Pécs Medical School, Pécs, HU

32 ⁶Insitute for Translational Medicine, University of Szeged Medical School, Szeged, HU
33
34
35
36
37
38

39 Key words: new-onset diabetes mellitus, pancreatic cancer, biomarker, screening
40
41
42

43 **Correspondence to:**

44 László Czakó, MD, PhD, DSc

45 First Department of Medicine,

46 University of Szeged,

47 Szeged, P.O.Box: 427, H-6701, Hungary

48 E-mail: czako.laszlo@med.u-szeged.hu

49 Telephone: +36-62-545187, Fax: +36-62-545185
50
51
52
53
54
55

56 Word count: 3909
57
58
59
60

Strengths and limitations of this study:

Strength 1: As patients are included prospectively, the study will yield a cohort to examine the metabolic changes that coincide with the occurrence of pancreatic cancer at a very early stage before it is diagnosed.

Strength 2: The criteria for the diagnoses of diabetes and pancreatic cancer will be uniformly applied throughout the study period, moreover the diagnosis of pancreatic cancer will be confirmed with a high level of certainty in all subjects.

Strength 3: Taking part in the screening is connected to a very low burden, as the blood collection is only minimally invasive.

Strength 4: All patients will be monitored closely and frequently, which will increase the survival of all participants, especially the high-risk patients.

Limitation 1: It might be really difficult to include the required number of patients, considering that PaC is a rare disease, and the elderly population has more comorbidities which not even make our observation more difficult, but also leads to a higher follow-up loss during the 36 months.

INTRODUCTION

Pancreatic cancer (PaC) is a rare disease with a lifetime prevalence of 1.39%, but its prevalence is continuously increasing (1-3). The prognosis is extremely poor: it has the lowest five-year survival of all cancers, only 6% (4), and this rate has not significantly changed in the last 40 years (5). PaC is projected to be the third leading cause of cancer-related death by 2030 (6). The high mortality rate is a consequence of delayed diagnosis: in the absence of specific symptoms, PaC is often diagnosed at an advanced stage. Surgery is the only curative treatment at this moment. Unfortunately, only 20% of the patients are eligible for curative resection at the time of the diagnosis because of the presence of metastases and locoregional infiltration (7). The success in reducing the mortality rate of PaC is related to a significant extent to the development of early detection and prevention programs. An effective screening programme is needed for the early diagnosis of PaC in the asymptomatic stage to improve the prognosis. Due to the low lifetime prevalence, the population-based screening is neither feasible nor cost-effective. It is recommended that subjects at high risk of PaC should be screened (8).

Pancreatic cancer and diabetes mellitus

Patients with diabetes mellitus (DM) have an eight-fold higher risk of developing PaC within 2–3 years after the diagnosis of diabetes relative to the general population (9). In a meta-analysis which included 36

1
2
3 studies, individuals in whom DM had only recently been diagnosed (<4 years) had a 50% increased risk of
4 PaC as compared with individuals who had diabetes for >5 years (10). Another meta-analysis of 35 cohort
5 studies showed that DM was associated with an increased risk of PaC (summary relative risks (RRs)=1.94;
6 95% CI, 1.66–2.27). Interestingly, the risk decreased with the duration of diabetes (5.38 for <1 year, 1.95
7 for 1–4 years, and 1.49 for 5–9 years, 1.47 for ≥ 10 years), thus providing evidence that several diabetes in
8 PaC patients is caused by the cancer itself (11). In these cases, patients are actually suffering from diabetes
9 type 3c (T3cDM). Diabetes is already prevalent in small PaCs (12), and what is more important, that
10 diabetes occurs before the tumour is radiologically detectable (13). A population-based study found that
11 approximately 1% of patients with new-onset diabetes at age 50 or older will be diagnosed with PaC within
12 3 years of first meeting criteria for diabetes, and 56% of these within 6 months of meeting the criteria for
13 diabetes (9). Recognition of new-onset diabetes as an early manifestation of PaC could lead to diagnosis of
14 asymptomatic, early-stage PaC (14). In our recent prospective study, the prevalence of PaC in patients with
15 new-onset type 2 diabetes (T2DM) was significantly higher than in the general population (the value of the
16 Standardised Incidence Ratio for PaC in new-onset type 2 diabetic patients was 198.6 (95% CI = 6.25-
17 46.9)); therefore, screening seems to be beneficial for detecting PaC in this patient population (15). Weight
18 loss in patients with pancreatic carcinoma-associated DM often precedes the onset of diabetes, while new-
19 onset primary type 2 DM is typically associated with weight gain (16). The paradoxical development of
20 diabetes in the face of ongoing weight loss may be an important clue to diagnose pancreatic carcinoma in
21 patients with new onset of diabetes.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Screening modalities**

39
40
41 The carbohydrate antigen 19-9 (CA19-9) is currently the only blood-based biomarker in clinical use for
42 PaC. The sensitivity of this marker for PaC is 75%, the specificity is 90%, the positive predictive value is
43 69%, and the negative predictive value is 90% (17). These values fall below the required characteristics of
44 a reliable screening test (10, 18); therefore, serum CA19-9 measurement is not suitable for screening for
45 PaC. Imaging modalities represent the gold standard for diagnosing PaC. The first choice is transabdominal
46 ultrasound. The sensitivity of transabdominal ultrasonography in PaC diagnosis is only 50–70%. Its
47 accuracy is low in tumours <1 cm, which are usually operable and negatively influenced by obesity and
48 meteorism (19). Computer tomography has a better accuracy in diagnosing PaC; however, the low
49 prevalence of PaC and radiation exposure associated with the modality prevents it from being used as a
50 screening test. The odds for a correct diagnosis are also high employing endoscopic ultrasound or
51 endoscopic retrograde cholangiopancreatography (ERCP), but again the low prevalence of PaC in
52 combination with the burden of the endoscopic intervention to the patient preclude the application of these
53
54
55
56
57
58
59
60

1
2
3 diagnostic methods for screening. Furthermore, it is not economically feasible to employ computer
4 tomography or endoscopic imaging for screening as these methods are associated with high costs to the
5 healthcare system.
6
7

8 The success of the strategy of using new-onset diabetes as a screening tool to identify subjects with a high
9 likelihood of having asymptomatic PaC will depend on our ability to differentiate PaC-associated diabetes
10 from the more common type 2 diabetes. PaC-induced diabetes is thought to be a paraneoplastic
11 phenomenon involving the release of products from the tumour rather than a result of the destruction of the
12 pancreas due to malignant infiltration (20, 21). Data on incidence of PaC in new onset of DM is rare,
13 numbers of 0.25% (22), 0.85% (9), and 3.6% (23) have been reported. Therefore, to enable a diagnostic
14 follow-up of new onset of diabetes, a further enrichment of this group is needed (14, 24, 25), e.g. elderly
15 subjects (age is an independent risk factor for PaC), weight loss (26), or smoking.
16
17

18 A biomarker panel consisting of nine metabolites plus the established protein CA19-9 were recently
19 identified by Mayerle and colleagues with 89.9% sensitivity, 91.3% specificity and 99.8% negative
20 predictive value for differentiating PaC from chronic pancreatitis (27). Employing the same methods, a
21 biomarker panel for differential diagnosis between PaC and non-cancer-related diabetes was identified. The
22 metabolite signature needs validation in an independent test cohort, which will be enabled with the present
23 study. Provided the biomarker is validated, the panel could be effective for screening of the high-risk group
24 patients diagnosed with new-onset DM.
25
26

27 A screening test will be cost-effective if sensitivity exceeds 88% and specificity is given at 85%, if the costs
28 for the test are below \$400, and if we accept \$16 889 per quality-adjusted life-year (10).
29
30
31
32
33

34 35 36 37 38 39 **Aims of the project**

- 40 a) Estimate the incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes
 - 41 b) Diagnose pancreatic ductal adenocarcinoma in an early operable stage
 - 42 c) Validate a biomarker that distinguishes patients with PaC-caused T3cDM from patients with T2DM.
- 43
44
45
46
47
48

49 **METHODS AND ANALYSIS**

50 **Design**

51 This is a prospective, multicentre, observational cohort study aiming to validate a biomarker panel in the
52 early stage of PaC. The data collection is based on questionnaires and blood samples will be drawn from
53 all patients. The questionnaires (Form A at recruitment, Form B at every follow up visit) will be filled by
54 every included patients. This study was structured as the SPIRIT 2013 guide recommended (Figure 1)
55 (28).
56
57
58
59
60

Table 1. Diagnostic criteria of diabetes mellitus.

The inclusion criteria of this study are the following: (1) patients over 60 years of age; (2) diabetes

Parameter	Value and unit	Description
Fasting plasma glucose	≥ 126 mg/dL (7.0 mmol/L)	Fasting is defined as no caloric intake for at least 8 h.
2 h plasma glucose	≥ 200 mg/dL (11.1 mmol/L)	Oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
HbA1c	$\geq 6.5\%$ (48 mmol/mol)	The test should be performed in a laboratory using a method that is NGSP certified and standardised to the DCCT assay.
random plasma glucose	≥ 200 mg/dL (11.1 mmol/L)	In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.

diagnosed within six months (newly diagnosed) - diagnostic criteria are based on the Diabetes Control and Complications Trial (Table 1. (29)); (3) signed written informed consent.

Exclusion criteria are as follows: (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; and (5) present malignant disease.

Sample size

20 cases in which PaC developed during follow-up. Considering a 105 drop-out rate, this means 2522 samples from follow-up patients over 60 years of age with diabetes diagnosed within 6 months and 250 matched patients in the control group.

Duration:

The first recruiting centre will be initialized in 1 July 2019. The planned finishing date of the study is January 31 December 2022.

Clinical data and clinical endpoints:

Essential baseline clinical data: age, sex, body weight, BMI, date of DM diagnosis, date of sampling, comorbidities, antidiabetic medication, clinical symptoms, histology and stage of pancreatic carcinoma.

Primary clinical endpoints: incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes

Secondary endpoints:

1
2
3 (1) mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients; (2) the proportion of
4 localised and resectable pancreatic ductal adenocarcinoma; (3) change in body weight before Visit 1 and
5 during Visit 2-6; (4) change in fasting blood glucose and HbA1c before Visit 1 and during Visit 2-6; (5)
6 antidiabetic medications and the risk of pancreatic ductal adenocarcinoma; (6) presence of concomitant
7 diseases; (7) smoking and alcohol intake; (8) the sensitivity, specificity, positive and negative predictive
8 values, and accuracy of the biomarker test; (9) cost-benefit analysis.
9
10
11
12
13
14

15 **Study protocol:**

16
17 Diabetic patients will be recruited by our diabetologist and collaborating family physicians based on a
18 recent (< 6 months) laboratory test (Table 1). Visit 0 is scheduled within 2 weeks from the referral
19 (Figure 2). Patients who meet study entry criteria and no exclusion, will be informed and offered to
20 participate in the study, however signed informed consent will be necessary for inclusion. Clinical data,
21 body weight and worrisome features (unintentional weight loss: 5% of body weight within 6 months
22 without knowing the reason (30), abdominal pain/discomfort, abnormal laboratory data, unstable glucose
23 metabolism despite the adequate diet and medical treatment and without intercurrent infection) will be
24 recorded at Visit 0, and a fasting blood sample will be taken for assessment of laboratory data and
25 metabolomics. C-peptide and glutamic acid decarboxylase antibodies (GADA) will be determined to
26 classify diabetes at Visit 0. If worrisome features are present at Visit 0, MRI or EUS is performed.
27 Unambiguous PaC lesions (>1 cm or seen also by magnetic resonance imaging) will be referred to surgery
28 for resection. In case of ambiguous lesions in the pancreas, EUS-fine needle aspiration will be performed.
29 Visit 1-5 are scheduled every 6 months. Clinical symptoms, body weight, laboratory data (fasting blood
30 glucose, HbA1c, liver and renal function, lipids, blood count) will be collected at each visit. Blood to
31 biobank and CA 19-9 will be taken at every 12 months. The follow-up will be closed at 36 months.
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Biochemical methods**

46
47 After informed consent, fasted (overnight, at least 8 h) patients' blood samples will be drawn into an EDTA
48 tube. 9 ml blood tubes are centrifuged within 2 h after blood draw using a swing-out rotor at 2000 xg for
49 10 minutes. The sample processing is done at room temperature and the centrifuge is temperature-controlled
50 at 19-21°C. After centrifugation, the supernatant is carefully removed, transferred to a fresh 9 ml tube and
51 gently mixed in order to homogenise any gradient that might have been generated in the plasma supernatant.
52 After that, the plasma is transferred in 0.5 ml aliquots to tubes (either Eppendorf Safe-Lock-Tubes 2 ml or
53 Sarstedt Screw cap micro tubes 2 ml) and stored at -80°C, in a dedicated freezer (≤6 h from centrifuge to
54 freezer). Biomarkers will be determined comparing metabolite levels in plasma samples from patients
55
56
57
58
59
60

1
2
3 diagnosed with PaC and diabetic cancer-free patients (26). CA19-9 determination is performed centralised
4 at a certified clinical laboratory applying a cut-off of 37 U/ml as a classifier.

5
6 Cost of the biomarker test, quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio
7 (ICER) will be determined.
8
9

10 11 **Metabolite profiling:**

12 **MxP® Global Profiling:**

13
14 Two types of mass spectrometry analyses are applied. GC-MS (gas chromatography-mass spectrometry;
15 Agilent 6890 GC coupled to an Agilent 5973 MS System, Agilent, Waldbronn, Germany) and LC-MS/MS
16 (liquid chromatography-MS/MS; Agilent 1100 HPLC-System, Agilent, Waldbronn, Germany, coupled to
17 an Applied Biosystems API4000 MS/MS-System, Applied Biosystems, Darmstadt, Germany) are used for
18 a metabolite profiling approach (31). Fractionation and derivatisation of samples and detection technologies
19 have been previously described (32-35). Proteins are removed from plasma samples (60 µl) by
20 precipitation. Subsequently, polar and non-polar fractions are separated for both GC-MS and LC-MS/MS
21 analyses by adding water and a mixture of ethanol and dichloromethane. For GC-MS analyses, the non-
22 polar fraction is treated with methanol under acidic conditions to yield the fatty acid methyl esters derived
23 from both free fatty acids and hydrolysed complex lipids. The polar and non-polar fractions are further
24 derivatised with O-methyl-hydroxylamine hydrochloride (20 mg/ml in pyridine) to convert oxo-groups to
25 O-methyloximes and subsequently with a silylating agent (N-Methyl-N-(trimethylsilyl) trifluoroacetamide)
26 before GC-MS analysis. For LC-MS/MS analyses, both fractions are dried and subsequently reconstituted
27 in appropriate solvent mixtures. HPLC (High performance LC) is performed by gradient elution using
28 methanol/water/formic acid on reversed phase separation columns.
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **MxP® Lipids:**

44 MxP® Lipids covers profiling of sphingolipids (ceramides, sphingomyelins, and sphingobases). The
45 metabolites are analysed in a semi-quantitative approach (i.e. relative to a pool). Total lipids are extracted
46 from plasma by liquid/liquid extraction using chloroform/methanol. The lipid extracts are subsequently
47 fractionated by normal phase liquid chromatography (NPLC) into different lipid groups according to (32,
48 36). The fractions are analysed by LC-MS/MS using electrospray ionization (ESI) and atmospheric pressure
49 chemical ionization (APCI) with detection of specific multiple reaction monitoring (MRM) transitions for
50 sphingomyelins (SM) and ceramides (CER) respectively.
51
52
53
54
55
56
57

58 **Data normalization**

1
2
3 Details of data normalization have been published (27). Metabolite profiling based on a semi-quantitative
4 analytical platform results in relative metabolite levels (“ratio”) to a defined reference. To support this
5 concept and to allow an alignment of different analytical batches, two different reference sample types are
6 run in parallel throughout the whole process. First, a project pool is generated from aliquots of all samples
7 and measured with four replicates within each analytical sequence that comprised 24 samples. For all semi-
8 quantitatively analysed metabolites, the results of each analyte from each sample are normalised against
9 the median of the corresponding analyte in the pool reference samples within each analytical sequence to
10 provide pool-normalised ratios. This process step compensates for inter- and intra-instrumental variation,
11 i.e. variability that occurs when different analytical sequences are analysed by different devices. Second, to
12 allow for an experiment-to-experiment alignment of semi-quantitative data, MxPool™ (a large pool of a
13 commercial human EDTA plasma suited for alignment of MxP® studies) is analysed with 12 replicated
14 samples, and the pool-normalised ratios are further normalised to the median of the MxPool™ samples, i.e.
15 ratios from this study are on the same level and therefore comparable with data from other studies
16 normalised to other aliquots of the same MxPool™. A rigorous quality control is performed on peak,
17 analyte and sample level and has been described previously (37).
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Data collection and follow-up**

32 Data collection is based on questionnaires, and will be stored in a personalised electronic database (eCRF).
33 Form A: contains all antropometric parameters, routine clinical chemistry tests, fasting blood glucose and
34 HbA1c. Follow-up visits will be scheduled by the patient registration system every 6 months. Blood will
35 be taken for biomarker identification with metabolomics and CA19-9 determination at every 12 months.
36 The total follow-up period is three years.
37
38
39
40
41 Pancreas adenocarcinoma will be diagnosed by histological examination.
42
43
44

45 **STATISTICS**

46 **Data set analysis and normalization**

47 Descriptive statistics – mean, median, standard deviation, quartiles and relative frequency –relative risk
48 (dichotomous variables), Independent Two-sample T test (continuous variable) in the case of normal
49 distribution, furthermore Mann-Whitney test in lack of normal distribution will be performed. Logistic
50 regression will be applied for the exploring of predictive factors. Affiliated statistical analyses will be
51 performed with an error probability of 0.05 (type-I error probability).
52
53
54
55

56 Prior to statistical analysis, log10 transformation of ratios is conducted so that the data distribution becomes
57 approximately normal. SIMCA-P version 14.0 (Umetrics AB, Umea, Sweden), TIBCO® Spotfire® 7.12.0
58
59
60

1
2
3 and R 3.3.4 are used for data analyses and visualizations. Initially, an exploratory multivariate analysis
4 (Principal Component Analysis, PCA) is applied to log₁₀-transformed ratios scaled to unit variance.

5
6 A simple linear model (ANOVA, package nlme) addressing additional clinical information and potentially
7
8 confounding factors such as “disease”, “age”, “body mass index”, “gender” and “sample storage time” as
9
10 fixed effects is fitted to the data. Significance level is set to 5%. The multiple test problem for the number
11
12 of metabolites is addressed by calculating the false discovery rate (FDR) using the Benjamini & Hochberg
13
14 method (38).

15 To classify patients depending on their metabolic profiles a penalised logistic regression is fitted via Elastic
16
17 Net Algorithm using the R package glmnet (38). Equal penalties are used for both the L1 and the L2 norm.
18
19 Afterwards the cutoff established previously on the biomarker identification dataset is applied on the test
20
21 data without retraining, and the performance is measured in terms of area under the curve (AUC), sensitivity
22
23 and specificity. Confidence levels for the AUC are calculated using the binormal model for the receiver
24
25 operating characteristic (ROC) curve. When the sensitivity is fixed at a particular value, the positive and
26
27 negative predictive values (PPV, NPV) and the accuracy become monotone functions of the specificity;
28
29 and confidence intervals for these estimates are obtained by transformation of the confidence interval for
30
31 the specificity. Confidence intervals for sensitivity, specificity and accuracy are obtained for the cutoff pre-
32
33 specified in the training data by the method of Clopper and Pearson for the binomial distribution. For PPV
34
35 and NPV the confidence intervals will be obtained by the method of Gart and Nam (39) for ratios of
36
37 binomial parameters as implemented in the R package pairwise CI (40). When comparing the biomarker
38
39 and CA19-9 on the test data, differences in sensitivity and specificity will be tested for with the McNemar
40
41 test.

41 **Centres**

42
43 The study will start with the following centres (University of Szeged, University of Pécs, University of
44
45 Semmelweis), however, other centres are welcome to participate as an open label study. Completion of the
46
47 LETTER OF INTENT form will be mandatory for registering the participation of each institution.

48 49 **Publication policy**

50
51 Centres providing more than 50 patients can provide author to the authorship list.

52 53 54 **Dissemination policy**

55
56 We plan to disseminate the results to several members of the healthcare system including medical doctors,
57
58 dietitians, nurses, patients etc. We plan to publish the results in a peer-reviewed high quality journal for
59
60

professionals. In addition, we also plan to publish it for lay readers in order to maximize the dissemination and benefits of this trial.

Patients and public involvement

Patients will be provided with informational material about the background and aims of the study.

Discussion

PaC has a dismal prognosis, which is due to its late diagnosis. The success in reducing the mortality rate of PaC is related to the development of early detection and prevention programs. Age and DM are known as risk factors of PaC (9-11, 14, 15).

The expected positive endpoint of this study is to validate a biomarker panel that is suitable for early stage diagnosis in a mostly incurable, high-mortality cancer, when surgery is still possible and the cancer can be cured. This test only requires one blood sample collection, which means that it is simple, repeatable, tolerable, minimally invasive, nearly painless, widely achievable and relatively cheap – it thus fulfils all the criteria set for a screening method. Identifying PaC in an earlier (still resectable) stage through surveillance of high-risk patients would increase surgical resection rate, cure rates and survival by 30–40%. It would save lives, maintain better well-being among the population and would have an enormous financial benefit: the increasing number of successful surgical interventions leads to a lower necessity of chemotherapy and palliative interventions (such as stent implantations or gastroenteroanastomosis operations), moreover lower the burden the healthcare cost.

Trial organization, committees and boards: The coordinator of the NODES study is LC with the support of the Hungarian Pancreatic Study Group (HPSG-coordinating society, <https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/>). HPSG has been running high-quality international, multicentre clinical trials since 2014 and has published the relevant guidelines for pancreatic diseases to improve patient care in pancreatology (41-49).

The trial will be supported by the following committees:

Steering Committee (SC): This committee will be led by PH (gastroenterologist and internal medicine specialist). The members in Szeged (HU) will be: Dóra Illés, Emese Ivány.

International Translational Advisory Board (ITAB): This board will involve gastroenterologists. The ITAB will regularly monitor the progression of the trial and might give recommendations to the SC.

1
2
3 Data Monitoring Committee (DMC): DMC will handle all the data and ensure that the data in the eCRF is
4 accurate, complete and legible. Data Management Plan (DMP) will describe the detailed data flow. The
5 Data Manager will validate the data from completed eCRFs, according to a Data Cleaning Plan (DCP). Any
6 missing, implausible or inconsistent recordings in the eCRFs will be referred back to the Investigator using
7 a data query form (DQF), and be documented for each individual subject before clean file status is declared.
8 All changes to eCRFs will be recorded.
9
10
11
12

13 14 ACKNOWLEDGEMENTS

15 16 **Funding**

17 The study was supported by National Research, Development and Innovation Office grants (K128222 to
18 LC). Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical
19 School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic
20 Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the
21 National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-
22 125678 and EFOP 3.6.2-16-2017-00006 Live Longer).
23
24
25
26
27
28

29 **Authors' contributions**

30 The study was designed by ID, LC, BK. ID, LC, MGA drafted the manuscript. All authors edited, read
31 and approved the final manuscript. Literature search, statistical calculation and figures preparation will be
32 done by JA, NZ, AS. During the study ID, EI, GH, KK, HV, GZ, MT, MS, VH, LC are going to collect
33 the patients.
34
35
36
37

38 39 **CONFLICT OF INTEREST STATEMENT**

40 BK and MGA are employees of Metanomics Health GmbH, Germany.
41
42

43 The other authors have no competing interest.
44
45
46

47 48 **ETHICS AND DISSEMINATION**

49 **Trial registration:** The trial has been registered at the ClinicalTrials.gov (NCT04164602)

50 **Ethical approval:** Scientific and Research Ethics Committee of the Hungarian Medical Research Council
51 (41085-6/2019).
52

53 Protocol Version: V1.0 08.01.2019.
54

55 Start of the patient recruitment: January 31, 2020.
56

57 Planned finish of the study: June 30, 2023
58
59
60

Abbreviations:

1
2
3
4
5 APCI - atmospheric pressure chemical ionization
6
7 AUC – area under the curve
8
9 CA 19-9 – carbohydrate antigen 19-9
10
11 CER – ceramides
12
13 DM – diabetes mellitus
14
15 DMC - Data Monitoring Committee
16
17 ERCP – endoscopic retrograde cholangio-pancreatography
18
19 ESI - electrospray ionization
20
21 EUS – endoscopic ultrasound
22
23 FDR - false discovery rate
24
25 GC-MS - gas chromatography-mass spectrometry
26
27 HbA1c – haemoglobin A1c
28
29 HPSG – Hungarian Pancreatic Study Group
30
31 ITAB - International Translational Advisory Board
32
33 LC- MS/MS - liquid chromatography-MS/MS
34
35 MRI – magnetic resonance imaging
36
37 MRM - multiple reaction monitoring
38
39 NPLC - normal phase liquid chromatography
40
41 NPV – negative predictive value
42
43 PaC – pancreatic cancer
44
45 PCA - principal component analysis
46
47 PPV – positive predictive value
48
49 ROC - receiver operating characteristic
50
51 SC - Steering Committee
52
53 SM – sphingomyelins
54
55 SP –Sponsor
56
57 T2DM – type 2 diabetes mellitus
58
59 T3cDM – type 3c diabetes mellitus
60

REFERENCES

1. National Cancer Institute. SEER Cancer Statistics Review 1975-2006.

- 1
- 2
- 3 2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world.
- 4 HPB (Oxford) 2008;10:58-62.
- 5
- 6 3. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. *Ann*
- 7 *Oncol* 2013;24:792-800.
- 8
- 9
- 10 4. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
- 11 Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on
- 12 Cancer; 2013. Available from: <http://globocan.iarc.fr>. Accessed December 2013.
- 13
- 14
- 15 5. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014; 64: 9-29.
- 16
- 17 6. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected
- 18 burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014;74:2913-21.
- 19
- 20 7. Gillen S, Schuster T, Meyer ZBC, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a
- 21 systematic review and meta-analysis of response and resection percentages. *PLoS Med* 2010;7:
- 22 e1000267.
- 23
- 24
- 25 8. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH et al. Advances
- 26 in counselling and surveillance patients at risk for pancreatic cancer. *Gut* 2007;56:1460-9.
- 27
- 28 9. Chari ST, Leibson CL, de Andrade M, et al. Probability of pancreatic cancer following diabetes:
- 29 population-based study. *Gastroenterology*. 2005;129:504-511.
- 30
- 31
- 32 10. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II
- 33 diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer*. 2005;92(11):2076-83.
- 34
- 35
- 36 11. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer:
- 37 a meta-analysis of cohort studies. *Eur. J. Cancer* 2011;47:1928-1937.
- 38
- 39
- 40 12. Tsuchiya R, et al. Collective review of small carcinomas of the pancreas. *Ann Surg*. 1986;203:77-81.
- 41
- 42 13. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic
- 43 cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose
- 44 values prior to diagnosis. *Am J Gastroenterol*. 2007;102:2157-2163.
- 45
- 46 14. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis
- 47 of pancreatic cancer. *Lancet Oncol*. 2009;10:88-95.
- 48
- 49 15. Illés D, Terzin V, Holzinger G, Kosár K, Róka R, Zsóri G, Ábrahám G, Czakó L. New-onset type 2
- 50 diabetes mellitus--A high-risk group suitable for the screening of pancreatic cancer? *Pancreatol*.
- 51 2016;16(2):266-71.
- 52
- 53
- 54 16. Hart PA1, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, Chari ST. Weight loss precedes
- 55 cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. *Pancreas*. 2011;40(5):768-
- 56 72.
- 57
- 58
- 59
- 60

17. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. *J Gastroenterol Hepatol*. 2004;19(2):182-6.
18. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. *Inhal Toxicol*. 2014;26(13):811-28.
19. Rickes S, Unkrodt K, Neye H, Ocran KW, Wermke W. Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echoenhanced power Doppler sonography. *Scand J Gastroenterol* 2002;37:1313-20.
20. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, and Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. *Gastroenterology* 2008;134:981-987.
21. Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, et al. Adrenomedullin up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. *Gastroenterology* 2012;143:1510–1517.
22. Munigala S, Singh A, Gelrud A, Agarwal B. Predictors for Pancreatic Cancer Diagnosis Following New-Onset Diabetes Mellitus. *Clin Transl Gastroenterol* 2015;6:e118.
23. Choe JW, Kim JS, Kim HJ, Hwang SY, Joo MK, Lee BJ et al. Value of Early Check-Up of Carbohydrate Antigen 19- 9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. *Pancreas* 2016;45:730-4.
24. Muniraj T, Chari ST. Diabetes and pancreatic cancer. *Minerva gastroenterologica e dietologica* 2012;58:331-45.
25. Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK et al. Early detection of sporadic pancreatic cancer: summative review. *Pancreas* 2015;44:693-712.
26. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. *Nat Rev Gastroenterol Hepatol* 2013;10:423-33.
27. Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. *Gut*. 2018;67(1):128-137.
28. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.
29. American Diabetes Association: Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. *Diabetes Care* 2018 Jan; 41(Supplement 1): S13-S27.
30. Rabinovitz M et al. Unintentional weight loss. A retrospective analysis of 154 cases. *Arch Intern Med* 1986;146(1):186-7

- 1
2
3 31. Jung K, Reszka R, Kamlage B, Bethan B, Stephan C, Lein M, Kristiansen G. Tissue metabolite
4 profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. *Int J Cancer*
5 2013;n/a.
6
7
- 8 32. Christie WW. Rapid separation and quantification of lipid classes by high performance liquid
9 chromatography and mass (light-scattering) detection. *J Lipid Res* 1985;26:507-12.
10
- 11 33. Mutch DM, Fuhrmann JC, Rein D, Wiemer JC, Bouillot JL, Poitou C, Clement K. Metabolite Profiling
12 Identifies Candidate Markers Reflecting the Clinical Adaptations Associated with Roux-en-Y Gastric
13 Bypass Surgery. *Plos One* 2009;4.
14
15
- 16 34. Roessner U, Wagner C, Kopka J, Trethewey RN, Willmitzer L. Technical advance: simultaneous
17 analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. *Plant J*
18 2000;23:131-42.
19
20
- 21 35. van Ravenzwaay B, Cunha GCP, Leibold E, Looser R, Mellert W, Prokoudine A et al. The use of
22 metabolomics for the discovery of new biomarkers of effect. *Toxicology Letters* 2007;172:21-8.
23
24
- 25 36. Schmidt H, Schmidt R, Geisslinger G. LC-MS/MS-analysis of sphingosine-1-phosphate and related
26 compounds in plasma samples. *Prostaglandins & Other Lipid Mediators* 2006;81:162-70.
27
28
- 29 37. Meller S, Meyer HA, Bethan B, Dietrich D, Maldonado SG, Lein M et al. Integration of tissue
30 metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific
31 metabolomic alterations in prostate cancer. *Oncotarget* 2016;7:1421-38.
32
33
- 34 38. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - A Practical and Powerful Approach
35 to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological* 1995;57:289-
36 300.
37
38
- 39 39. Gart JJ, Nam J. Approximate interval estimation of the ratio of binomial parameters: a review and
40 corrections for skewness. *Biometrics* 1988;44:323-38.
41
42
- 43 40. Scherer R, Schaarschmidt F, Prescher S, Priesnitz KU. Simultaneous confidence intervals for
44 comparing biodiversity indices estimated from overdispersed count data. *Biometrical Journal*
45 *Biometrische Zeitschrift* 2013;55:246-63.
46
47
- 48 41. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk
49 stratification in acute pancreatitis. *J Gastrointestin Liver Dis* 2015;24(2):177-82. doi:
50 10.15403/jgld.2014.1121.242.easy
51
52
- 53 42. Párniczky A, Mosztabacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-
54 study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):105-10. doi:
55 10.1159/000441353
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
43. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis (PINEAPPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):121–6. doi: 10.1159/000441352
 44. Dubravcsik Z, Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of acute biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective, randomized, interventional, controlled trial. *Pancreatology* 2015;15(2):115–23. doi: 10.1016/j.pan.2015.02.007
 45. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ Open* 2017;7(9):e015874. doi: 10.1136/bmjopen-2017-015874
 46. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):292–307. doi: 10.1556/OH.2015.30061
 47. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61. doi: 10.1556/OH.2015.30059
 48. Párniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25. doi: 10.1556/OH.2015.30062
 49. Takacs T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88. doi: 10.1556/OH.2015.30060

Figure 1. The schedule of enrolment and assessments according to the SPIRIT guideline


	STUDY PERIOD							
	Enrolment	Post enrolment					Close-out	
TIMEPOINT	0	Visit1	Visit2	Visit3	Visit4	Visit5	Visit6	t _x
		0.5 y	1 y	1.5 y	2 y	2.5y	3y	
ENROLMENT:								
Eligibility screen	X							
Informed consent	X							
FORM A	X							
Blood samples to biobank	X							
VISITS:								
FORM B		X	X	X	X	X	X	
Laboratory test		X	X	X	X	X	X	
Blood samples to biobank*	X		X		X		X	
MRI/EUS if worrisome features are present	X	X	X	X	X	X	X	
DATA ANALYSIS:								X

*Fasted (overnight, at least 8 h) patients' blood samples at room temperature will be drawn into an EDTA tube.

Within 2 h after blood draw samples will be at 19-21°C. After centrifugation, the supernatant is carefully removed.

After that, the plasma is transferred in 0.5 ml aliquots to tubes and stored at -80°C, in a dedicated freezer (≤6 h from centrifuge to freezer). Central laboratory: Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany

Figure 2. Flowchart of the study protocol



* weight loss (except at visit0), abdominal pain/discomfort, abnormal laboratory data, unstable glucose metabolism despite the adequate diet and medical treatment and without intercurrent infection (except at visit0)
EUS: endoscopic ultrasound; MRI: magnetic resonance imaging

** Fasted (overnight, at least 8 h) patients' blood samples at room temperature will be drawn into an EDTA tube. Within 2 h after blood draw samples will be at 19-21°C. After centrifugation, the supernatant is carefully removed. After that, the plasma is transferred in 0.5 ml aliquots to tubes and stored at -80°C, in a dedicated freezer (≤6 h from centrifuge to freezer).

BMJ Open

New Onset of Diabetes in a Association with pancreatic ductal adenocarcinoma (NODES trial): Protocol of a Prospective, Multicentre Observational trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037267.R1
Article Type:	Protocol
Date Submitted by the Author:	15-May-2020
Complete List of Authors:	<p>Illés, Dóra; University of Szeged Faculty of Medicine, First Department of Medicine Ivány, Emese ; University of Szeged Faculty of Medicine, First Department of Medicine Holzinger, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Kosár, Klára; University of Szeged Faculty of Medicine, First Department of Medicine Volosinovszki, Hajnalka; University of Szeged Faculty of Medicine, First Department of Medicine Gordian, Adam M.; Metanomics Health GmbH Kamlage, Beate; Metanomics Health GmbH Zsóri, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Tajti, Máté; University of Szeged Faculty of Medicine, First Department of Medicine Svébis, Márk ; Semmelweis University of Medicine, 1. Department of Internal Medicine Horváth, Viktor; Semmelweis University of Medicine, 1. Department of Internal Medicine Oláh, Ilona; Ilona Tóth Outpatient Clinic Márta, Katalin; Institute for Translational Medicine, University of Pécs Medical School, ; János Szentágothai Research Center, University of Pécs, Váncsa, Szilárd; Institute for Translational Medicine, University of Pécs Medical School; János Szentágothai Research Center, University of Pécs, Zádori, Noémi; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Szentesi, Andrea; Pecs Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group Hegy, Péter; Pecs Tudományegyetem Általános Orvostudományi Kar, Institution for Translational Medicine Czakó, László; University of Szeged, First Department of Medicine</p>
Primary Subject Heading:	Diabetes and endocrinology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Pancreatic disease < GASTROENTEROLOGY, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 ***New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES trial):***
7

8 ***Protocol of a Prospective, Multicentre Observational trial***
9
10
11
12

13 Dóra Illés¹, Emese Ivány¹, Gábor Holzinger¹, Klára Kosár¹, Hajnalka Volosinovszki¹, M. Gordian Adam²,
14 Beate Kamlage², Gábor Zsóri¹, Máté Tajti¹, Márk Svébis³, Viktor Horváth³, Ilona Oláh⁴, Katalin Márta⁵,
15 Szilárd Vánca⁵, Noémi Zádori⁵, Andrea Szentesi⁶, Péter Hegyi^{5,6}, László Czakó¹
16
17
18
19
20
21
22
23
24
25
26

27 ¹First Department of Medicine University of Szeged, Szeged, HU

28 ²Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany

29 ³ First Department of Medicine University of Semmelweis, Budapest, HU

30 ⁴Ilona Tóth Outpatient Clinic, Diabetes Care, Budapest, HU

31 ⁵Insitute for Translational Medicine, Medical School, University of Pécs Medical School, Pécs, HU

32 ⁶Insitute for Translational Medicine, University of Szeged Medical School, Szeged, HU
33
34
35
36
37
38

39 Key words: new-onset diabetes mellitus, pancreatic cancer, biomarker, screening
40
41

42 **Correspondence to:**

43 László Czakó, MD, PhD, DSc

44 First Department of Medicine,

45 University of Szeged,

46 Szeged, P.O.Box: 427, H-6701, Hungary

47 E-mail: czako.laszlo@med.u-szeged.hu

48 Telephone: +36-62-545187, Fax: +36-62-545185
49
50
51
52
53
54
55

56 Word count: 3755
57
58
59
60

ABSTRACT

Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with an overall 5-year survival of approximately 8%. The success in reducing the mortality rate of PDAC is related not only to the discovery of new therapeutic agents, but also to a significant extent to the development of early detection and prevention programs. Patients with new-onset diabetes mellitus represent a high-risk group for PDAC as they have an 8-fold higher risk of PDAC than the general population. The proposed screening program may allow the detection of PDAC in the early, operable stage. Diagnosing more patients in the curable stage might decrease the morbidity and mortality rates of PDAC and additionally reduce the burden of the healthcare.

Methods & Analysis: This is a prospective, multicentre observational cohort study. Patients ≥ 60 years old diagnosed with new-onset (≤ 6 months) diabetes will be included. Exclusion criteria are (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; (5) present malignant disease and (6) type-1 diabetes mellitus. Follow up visits are scheduled every 6 months for up to 36 months. Data collection is based on questionnaires. Clinical symptoms, body weight and fasting blood will be collected at each, CA 19-9 and blood to biobank at every second visit. The blood samples will be processed to plasma and analysed with mass spectrometry-based metabolomics. The metabolomic data will be used for biomarker validation for early detection of PDAC in the high-risk group new-onset diabetes patients. Patients with worrisome features will undergo MRI or EUS investigation, and surgical referral depending on the radiological findings. The primary endpoint is the incidence of PDAC in patients with newly diagnosed diabetes mellitus.

Ethical approval: Scientific and Research Ethics Committee of the Hungarian Medical Research Council (41085-6/2019).

Trial registration: The trial has been registered at the ClinicalTrials.gov (NCT04164602).

Strengths and limitations of this study:

Strength 1: As patients are included prospectively, the study will yield a cohort to examine the metabolic changes that coincide with the occurrence of PDAC at a very early stage before it is diagnosed.

Strength 2: The criteria for the diagnoses of diabetes and PDAC will be uniformly applied throughout the study period, moreover the diagnosis of pancreatic cancer will be confirmed with a high level of certainty in all subjects.

Strength 3: Taking part in the screening is connected to a very low burden, as the blood collection is only minimally invasive.

Strength 4: All patients will be monitored closely and frequently, which will increase the survival of all participants, especially the high-risk patients.

Limitation 1: It might be really difficult to include the required number of patients, considering that PDAC is a rare disease, and the elderly population has more comorbidities which not even make our observation more difficult, but also leads to a higher follow-up loss during the 36 months.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is a rare disease with a lifetime prevalence of 1.39%, but its prevalence is continuously increasing (1-3). The prognosis is extremely poor: it has a five-year survival rate of only 7-8% (4), and this rate has barely improved in the last 40 years (5). PDAC will be the second leading cause of cancer-related death by 2030 (6). The high mortality rate is a consequence of delayed diagnosis: in the absence of specific symptoms, PDAC is often diagnosed at an advanced stage. Surgery is the only curative treatment at this moment. Unfortunately, only 20% of the patients are eligible for curative resection at the time of the diagnosis because of the presence of metastases and locoregional infiltration (7). The success in reducing the mortality rate of PDAC is related to a significant extent to the development of early detection and prevention programs. An effective screening programme is needed for the early diagnosis of PDAC in the asymptomatic stage to improve the prognosis. Due to the low lifetime prevalence, the population-based screening is neither feasible nor cost-effective. It is recommended that subjects at high risk of PDAC should be screened (8).

Pancreatic ductal adenocarcinoma and diabetes mellitus

Patients with diabetes mellitus (DM) have an eight-fold higher risk of developing PDAC within 2–3 years after the diagnosis of diabetes relative to the general population (9). In a meta-analysis which included 36

1
2
3 studies, individuals in whom DM had only recently been diagnosed (<4 years) had a 50% increased risk of
4 PDAC as compared with individuals who had diabetes for >5 years (10). Another meta-analysis of 35 cohort
5 studies showed that DM was associated with an increased risk of PDAC (summary relative risks
6 (RRs)=1.94; 95% CI, 1.66–2.27). Interestingly, the risk decreased with the duration of diabetes (5.38 for
7 <1 year, 1.95 for 1–4 years, and 1.49 for 5–9 years, 1.47 for ≥10 years), thus providing evidence that several
8 diabetes in PDAC patients is caused by the cancer itself (11). In these cases, patients are actually suffering
9 from diabetes type 3c (T3cDM). Diabetes is already prevalent in small PDACs (12), and what is more
10 important, that diabetes occurs before the tumour is radiologically detectable (13). A population-based
11 study found that approximately 1% of patients with new-onset diabetes at age 50 or older will be diagnosed
12 with PDAC within 3 years of first meeting criteria for diabetes, and 56% of these within 6 months of
13 meeting the criteria for diabetes (9). Recognition of new-onset diabetes as an early manifestation of PDAC
14 could lead to diagnosis of asymptomatic, early-stage PDAC (14). In our recent prospective study, the
15 prevalence of PDAC in patients with new-onset type 2 diabetes (T2DM) was significantly higher than in
16 the general population (the value of the Standardised Incidence Ratio for PDAC in new-onset type 2
17 diabetic patients was 198.6 (95% CI = 6.25-46.9)); therefore, screening seems to be beneficial for detecting
18 PDAC in this patient population (15). Weight loss in patients with pancreatic carcinoma-associated DM
19 often precedes the onset of diabetes, while new-onset primary type 2 DM is typically associated with weight
20 gain (16). The paradoxical development of diabetes in the face of ongoing weight loss may be an important
21 clue to diagnose PDAC in patients with new onset of diabetes.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Screening modalities**

38
39
40
41 The carbohydrate antigen 19-9 (CA19-9) is currently the only blood-based biomarker in clinical use for
42 PDAC. The sensitivity of this marker for PDAC is 75%, the specificity is 90%, the positive predictive value
43 is 69%, and the negative predictive value is 90% (17). These values fall below the required characteristics
44 of a reliable screening test (10, 18); therefore, serum CA19-9 measurement is not suitable for screening for
45 PDAC. Imaging modalities represent the gold standard for diagnosing PDAC. The first choice is
46 transabdominal ultrasound. The sensitivity of transabdominal ultrasonography in PDAC diagnosis is only
47 50–70%. Its accuracy is low in tumours <1 cm, which are usually operable and negatively influenced by
48 obesity and meteorism (19). Computer tomography has a better accuracy in diagnosing PDAC; however,
49 the low prevalence of PDAC and radiation exposure associated with the modality prevents it from being
50 used as a screening test. The odds for a correct diagnosis are also high employing endoscopic ultrasound or
51 endoscopic retrograde cholangiopancreatography (ERCP), but again the low prevalence of PDAC in
52 combination with the burden of the endoscopic intervention to the patient preclude the application of these
53
54
55
56
57
58
59
60

1
2
3 diagnostic methods for screening. Furthermore, it is not economically feasible to employ computer
4 tomography or endoscopic imaging for screening as these methods are associated with high costs to the
5 healthcare system.
6
7

8 The success of the strategy of using new-onset diabetes as a screening tool to identify subjects with a high
9 likelihood of having asymptomatic PDAC will depend on our ability to differentiate PDAC-associated
10 diabetes from the more common type 2 diabetes. PDAC-induced diabetes is thought to be a paraneoplastic
11 phenomenon involving the release of products from the tumour rather than a result of the destruction of the
12 pancreas due to malignant infiltration (20, 21). Data on incidence of PDAC in new onset of DM is rare,
13 numbers of 0.25% (22), 0.85% (9), and 3.6% (23) have been reported. Therefore, to enable a diagnostic
14 follow-up of new onset of diabetes, a further enrichment of this group is needed (14, 24, 25), e.g. elderly
15 subjects (age is an independent risk factor for PDAC), weight loss (26), or smoking.
16
17

18 A biomarker panel consisting of nine metabolites plus the established protein CA19-9 were recently
19 identified by Mayerle and colleagues with 89.9% sensitivity, 91.3% specificity and 99.8% negative
20 predictive value for differentiating PDAC from chronic pancreatitis (27). Employing the same methods, a
21 biomarker panel for differential diagnosis between PDAC and non-cancer-related diabetes was identified.
22 The metabolite signature needs validation in an independent test cohort, which will be enabled with the
23 present study. Provided the biomarker is validated, the panel could be effective for screening of the high-
24 risk group patients diagnosed with new-onset DM.
25
26

27 A screening test will be cost-effective if sensitivity exceeds 88% and specificity is given at 85%, if the costs
28 for the test are below \$400, and if we accept \$16 889 per quality-adjusted life-year (10).
29
30
31

32 33 34 35 36 37 38 39 **Aims of the project**

- 40 a) Estimate the incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes
- 41 b) Diagnose pancreatic ductal adenocarcinoma in an early operable stage
- 42 c) Validate a biomarker that distinguishes patients with PDAC-caused T3cDM from patients with
43 T2DM.
44
45
46
47
48
49
50

51 **METHODS AND ANALYSIS**

52 **Design**

53 This is a prospective, multicentre, observational cohort study aiming to validate a biomarker panel in the
54 early stage of PDAC. The data collection is based on questionnaires and blood samples will be drawn
55 from all patients. The questionnaires (Form A at recruitment, Form B at every follow up visit) will be
56 filled by every included patients.
57
58
59
60

Parameter	Value and unit	Description
Fasting plasma glucose	≥ 126 mg/dL (7.0 mmol/L)	Fasting is defined as no caloric intake for at least 8 h.
2 h plasma glucose	≥ 200 mg/dL (11.1 mmol/L)	Oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
HbA1c	$\geq 6.5\%$ (48 mmol/mol)	The test should be performed in a laboratory using a method that is NGSP certified and standardised to the DCCT assay.

Table 1. Diagnostic criteria of diabetes mellitus.

The inclusion criteria of this study are the following: (1) patients over 60 years of age; (2) diabetes diagnosed within six months (newly diagnosed) - diagnostic criteria are based on the Diabetes Control and Complications Trial (Table 1. (28)); (3) signed written informed consent.

Exclusion criteria are as follows: (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; and (5) present malignant disease; (6) type-1 diabetes mellitus.

Sample size

Chari et al. concluded that about 1% of elderly subjects with new-onset DM has 8 times higher risk for pancreatic cancer than for a person of similar age and sex without DM (9). Based on these results, we have an assumption with respect to cancerous cases of the distribution in the case and the control groups (Case: PDAC 1%, non-PDAC: 99%; Control: PDAC 0.125%, non-PDAC 99.875%). Sample size calculation suggests that 2552 patients (1:1) will need to be enrolled in order to confirm or reject the hypothesis for the primary endpoint with a 10% dropout, 80% power and 95% significance level. 250 patients with non-pancreatic, non-malignant gastrointestinal diseases without diabetes serve as control group. The recruitment period is planned to last 36 months, and all included patients will be followed for 36 months.

Duration:

The first recruiting centre will be initialized in 1 July 2019. Start of the patient recruitment: January 31, 2020. Planned finish of the study-recruitment: January 30, 2023.

Clinical data and clinical endpoints:

Essential baseline clinical data: age, sex, body weight, BMI, date of DM diagnosis, date of sampling, comorbidities, antidiabetic medication, clinical symptoms, histology and stage of PDAC.

1
2
3 Primary clinical endpoints: incidence of pancreatic ductal adenocarcinoma in patients with new-onset
4 diabetes
5

6
7
8 Secondary endpoints:
9

10 (1) mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients; (2) the proportion of
11 localised and resectable pancreatic ductal adenocarcinoma; (3) change in body weight before Visit 1 and
12 during Visit 2-6; (4) change in fasting blood glucose and HbA1c before Visit 1 and during Visit 2-6; (5)
13 antidiabetic medications and the risk of pancreatic ductal adenocarcinoma; (6) presence of concomitant
14 diseases; (7) smoking and alcohol intake; (8) the sensitivity, specificity, positive and negative predictive
15 values, and accuracy of the biomarker test; (9) cost-benefit analysis.
16
17
18
19
20
21

22 **Study protocol:**

23 Diabetic patients will be recruited by our diabetologist and collaborating family physicians based on a
24 recent (< 6 months) laboratory test (Table 1). Visit 0 is scheduled within 2 weeks from the referral
25 (Figure 1). Patients who meet study entry criteria and no exclusion, will be informed and offered to
26 participate in the study, however signed informed consent will be necessary for inclusion. Clinical data,
27 body weight and worrisome features (unintentional weight loss: 5% of body weight within 6 months
28 without knowing the reason (29), abdominal pain/discomfort, abnormal laboratory data, unstable glucose
29 metabolism despite the adequate diet and medical treatment and without intercurrent infection) will be
30 recorded at Visit 0, and a fasting blood sample will be taken for assessment of laboratory data and
31 metabolomics. C-peptide and glutamic acid decarboxylase antibodies (GADA) will be determined to
32 classify diabetes at Visit 0. Patients with type-1 diabetes mellitus will be excluded. If worrisome features
33 are present at Visit 0, MRI or EUS is performed. Unambiguous PaC lesions (>1 cm or seen also by magnetic
34 resonance imaging) will be referred to surgery for resection. In case of ambiguous lesions in the pancreas,
35 EUS-fine needle aspiration will be performed. Visit 1-5 are scheduled every 6 months. Clinical symptoms,
36 body weight, laboratory data (fasting blood glucose, HbA1c, liver and renal function, lipids, blood count)
37 will be collected at each visit. Blood to biobank and CA 19-9 will be taken at every 12 months. The follow-
38 up will be closed at 36 months.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Biochemical methods**

53 After informed consent, fasted (overnight, at least 8 h) patients' blood samples will be drawn into an EDTA
54 tube. 9 ml blood tubes are centrifuged within 2 h after blood draw using a swing-out rotor at 2000 xg for
55 10 minutes. The sample processing is done at room temperature and the centrifuge is temperature-controlled
56 at 19-21°C. After centrifugation, the supernatant is carefully removed, transferred to a fresh 9 ml tube and
57
58
59
60

1
2
3 gently mixed in order to homogenise any gradient that might have been generated in the plasma supernatant.
4 After that, the plasma is transferred in 0.5 ml aliquots to tubes (either Eppendorf Safe-Lock-Tubes 2 ml or
5 Sarstedt Screw cap micro tubes 2 ml) and stored at -80°C , in a dedicated freezer (≤ 6 h from centrifuge to
6 freezer). Biomarkers will be determined comparing metabolite levels in plasma samples from patients
7 diagnosed with PDAC and diabetic cancer-free patients (26). CA19-9 determination is performed
8 centralised at a certified clinical laboratory applying a cut-off of 37 U/ml as a classifier.
9
10 Cost of the biomarker test, quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio
11 (ICER) will be determined.
12
13
14
15
16
17

18 **Metabolite profiling:**

19 **MxP[®] Global Profiling:**

20
21 Two types of mass spectrometry analyses are applied. GC-MS (gas chromatography-mass spectrometry;
22 Agilent 6890 GC coupled to an Agilent 5973 MS System, Agilent, Waldbronn, Germany) and LC-MS/MS
23 (liquid chromatography-MS/MS; Agilent 1100 HPLC-System, Agilent, Waldbronn, Germany, coupled to
24 an Applied Biosystems API4000 MS/MS-System, Applied Biosystems, Darmstadt, Germany) are used for
25 a metabolite profiling approach (30). Fractionation and derivatisation of samples and detection technologies
26 have been previously described (31-34). Proteins are removed from plasma samples (60 μl) by
27 precipitation. Subsequently, polar and non-polar fractions are separated for both GC-MS and LC-MS/MS
28 analyses by adding water and a mixture of ethanol and dichloromethane. For GC-MS analyses, the non-
29 polar fraction is treated with methanol under acidic conditions to yield the fatty acid methyl esters derived
30 from both free fatty acids and hydrolysed complex lipids. The polar and non-polar fractions are further
31 derivatised with O-methyl-hydroxylamine hydrochloride (20 mg/ml in pyridine) to convert oxo-groups to
32 O-methyloximes and subsequently with a silylating agent (N-Methyl-N-(trimethylsilyl) trifluoroacetamide)
33 before GC-MS analysis. For LC-MS/MS analyses, both fractions are dried and subsequently reconstituted
34 in appropriate solvent mixtures. HPLC (High performance LC) is performed by gradient elution using
35 methanol/water/formic acid on reversed phase separation columns.
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **MxP[®] Lipids:**

50
51 MxP[®] Lipids covers profiling of sphingolipids (ceramides, sphingomyelins, and sphingobases). The
52 metabolites are analysed in a semi-quantitative approach (i.e. relative to a pool). Total lipids are extracted
53 from plasma by liquid/liquid extraction using chloroform/methanol. The lipid extracts are subsequently
54 fractionated by normal phase liquid chromatography (NPLC) into different lipid groups according to (31,
55 35). The fractions are analysed by LC-MS/MS using electrospray ionization (ESI) and atmospheric pressure
56
57
58
59
60

1
2
3 chemical ionization (APCI) with detection of specific multiple reaction monitoring (MRM) transitions for
4 sphingomyelins (SM) and ceramides (CER) respectively.
5
6
7

8 **Data normalization**

9
10 Details of data normalization have been published (27). Metabolite profiling based on a semi-quantitative
11 analytical platform results in relative metabolite levels (“ratio”) to a defined reference. To support this
12 concept and to allow an alignment of different analytical batches, two different reference sample types are
13 run in parallel throughout the whole process. First, a project pool is generated from aliquots of all samples
14 and measured with four replicates within each analytical sequence that comprised 24 samples. For all semi-
15 quantitatively analysed metabolites, the results of each analyte from each sample are normalised against
16 the median of the corresponding analyte in the pool reference samples within each analytical sequence to
17 provide pool-normalised ratios. This process step compensates for inter- and intra-instrumental variation,
18 i.e. variability that occurs when different analytical sequences are analysed by different devices. Second, to
19 allow for an experiment-to-experiment alignment of semi-quantitative data, MxPool™ (a large pool of a
20 commercial human EDTA plasma suited for alignment of MxP® studies) is analysed with 12 replicated
21 samples, and the pool-normalised ratios are further normalised to the median of the MxPool™ samples, i.e.
22 ratios from this study are on the same level and therefore comparable with data from other studies
23 normalised to other aliquots of the same MxPool™. A rigorous quality control is performed on peak,
24 analyte and sample level and has been described previously (36).
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection and follow-up**

39 Data collection is based on questionnaires, and will be stored in a personalised electronic database (eCRF).
40 Form A: contains all antropometric parameters, routine clinical chemistry tests, fasting blood glucose and
41 HbA1c. Follow-up visits will be scheduled by the patient registration system every 6 months. Blood will
42 be taken for biomarker identification with metabolomics and CA19-9 determination at every 12 months.
43 The total follow-up period is three years.
44
45
46

47 Pancreas adenocarcinoma will be diagnosed by histological examination.
48
49
50

51 **Data set analysis and normalization**

52 Descriptive statistics – mean, median, standard deviation, quartiles and relative frequency –relative risk
53 (dichotomous variables), Independent Two-sample T test (continuous variable) in the case of normal
54 distribution, furthermore Mann-Whitney test in lack of normal distribution will be performed. Logistic
55 regression will be applied for the exploring of predictive factors. Affiliated statistical analyses will be
56 performed with an error probability of 0.05 (type-I error probability).
57
58
59
60

1
2
3 Prior to statistical analysis, log₁₀ transformation of ratios is conducted so that the data distribution becomes
4 approximately normal. SIMCA-P version 14.0 (Umetrics AB, Umea, Sweden), TIBCO® Spotfire® 7.12.0
5 and R 3.3.4 are used for data analyses and visualizations. Initially, an exploratory multivariate analysis
6 (Principal Component Analysis, PCA) is applied to log₁₀-transformed ratios scaled to unit variance.
7
8

9
10 A simple linear model (ANOVA, package nlme) addressing additional clinical information and potentially
11 confounding factors such as “disease”, “age”, “body mass index”, “gender” and “sample storage time” as
12 fixed effects is fitted to the data. Significance level is set to 5%. The multiple test problem for the number
13 of metabolites is addressed by calculating the false discovery rate (FDR) using the Benjamini & Hochberg
14 method (37).
15
16

17
18 To classify patients depending on their metabolic profiles a penalised logistic regression is fitted via Elastic
19 Net Algorithm using the R package glmnet (37). Equal penalties are used for both the L1 and the L2 norm.
20 Afterwards the cutoff established previously on the biomarker identification dataset is applied on the test
21 data without retraining, and the performance is measured in terms of area under the curve (AUC), sensitivity
22 and specificity. Confidence levels for the AUC are calculated using the binormal model for the receiver
23 operating characteristic (ROC) curve. When the sensitivity is fixed at a particular value, the positive and
24 negative predictive values (PPV, NPV) and the accuracy become monotone functions of the specificity;
25 and confidence intervals for these estimates are obtained by transformation of the confidence interval for
26 the specificity. Confidence intervals for sensitivity, specificity and accuracy are obtained for the cutoff pre-
27 specified in the training data by the method of Clopper and Pearson for the binomial distribution. For PPV
28 and NPV the confidence intervals will be obtained by the method of Gart and Nam (38) for ratios of
29 binomial parameters as implemented in the R package pairwise CI (39). When comparing the biomarker
30 and CA19-9 on the test data, differences in sensitivity and specificity will be tested for with the McNemar
31 test.
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Centres**

46 The study will start with the following centres (University of Szeged, University of Pécs, University of
47 Semmelweis), however, other centres are welcome to participate as an open label study. Completion of the
48 LETTER OF INTENT form will be mandatory for registering the participation of each institution.
49
50

51 **PATIENTS AND PUBLIC INVOLVEMENT**

52
53 If possible, PPI will be included although the study is very specific and the actual scientific protocol can
54 only be done in one way, leaving little room for public involvement in the design.
55
56
57
58
59

60 **ETHICS AND DISSEMINATION**

1
2
3 **Trial registration:** The trial has been registered at the ClinicalTrials.gov (NCT04164602)

4 **Ethical approval:** Scientific and Research Ethics Committee of the Hungarian Medical Research Council
5 (41085-6/2019). Protocol Version: V1.0 08.01.2019.
6
7

8 **Publication policy**

9
10 Centres providing more than 50 patients can provide author to the authorship list.

11 **Dissemination policy**

12 We plan to disseminate the results to several members of the healthcare system including medical doctors,
13 dietitians, nurses, patients etc. We plan to publish the results in a peer-reviewed high quality journal for
14 professionals. In addition, we also plan to publish it for lay readers in order to maximize the dissemination
15 and benefits of this trial.
16
17
18
19

20 **DISCUSSION**

21
22 PDAC has a dismal prognosis, which is due to its late diagnosis. The success in reducing the mortality rate
23 of PDAC is related to the development of early detection and prevention programs. Age and DM are known
24 as risk factors of PDAC (9-11, 14, 15).
25
26
27

28 The expected positive endpoint of this study is to validate a biomarker panel that is suitable for early stage
29 diagnosis in a mostly incurable, high-mortality cancer, when surgery is still possible and the cancer can be
30 cured. This test only requires one blood sample collection, which means that it is simple, repeatable,
31 tolerable, minimally invasive, nearly painless, widely achievable and relatively cheap – it thus fulfils all
32 the criteria set for a screening method. Identifying PDAC in an earlier (still resectable) stage through
33 surveillance of high-risk patients would increase surgical resection rate, cure rates and survival by 30–40%.
34
35 It would save lives, maintain better well-being among the population and would have an enormous financial
36 benefit: the increasing number of successful surgical interventions leads to a lower necessity of
37 chemotherapy and palliative interventions (such as stent implantations or gastroenteroanastomosis
38 operations), moreover lower the burden the healthcare cost.
39
40
41
42
43
44
45
46

47 **Trial organization, committees and boards:** The coordinator of the NODES study is LC with the support
48 of the Hungarian Pancreatic Study Group (HPSG-coordinating society, [https://tm-centre.org/en/study-](https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/)
49 [groups/hungarian-pancreatic-study-group/](https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/)). HPSG has been running high-quality international,
50 multicentre clinical trials since 2014 and has published the relevant guidelines for pancreatic diseases to
51 improve patient care in pancreatology (40-48).
52
53
54

55 The trial will be supported by the following committees:
56
57
58
59
60

1
2
3 Steering Committee (SC): This committee will be led by PH (gastroenterologist and internal medicine
4 specialist). The members in Szeged (HU) will be: DI, EI.
5
6
7

8 International Translational Advisory Board (ITAB): This board will involve gastroenterologists. The ITAB
9 will regularly monitor the progression of the trial and might give recommendations to the SC.
10
11

12 Data Monitoring Committee (DMC): DMC will handle all the data and ensure that the data in the eCRF is
13 accurate, complete and legible. Data Management Plan (DMP) will describe the detailed data flow. The
14 Data Manager will validate the data from completed eCRFs, according to a Data Cleaning Plan (DCP). Any
15 missing, implausible or inconsistent recordings in the eCRFs will be referred back to the Investigator using
16 a data query form (DQF), and be documented for each individual subject before clean file status is declared.
17 All changes to eCRFs will be recorded.
18
19
20
21
22

23 ACKNOWLEDGEMENTS

24 **Funding**

25
26 The study was supported by National Research, Development and Innovation Office grants (K128222 to
27 LC). Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical
28 School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic
29 Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the
30 National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-
31 125678 and EFOP 3.6.2-16-2017-00006 Live Longer).
32
33
34
35
36
37

38 **Authors' contributions**

39
40 The study was designed by ID, LC, BK, PH. ID, LC, MGA drafted the manuscript. All authors edited,
41 read and approved the final manuscript. Literature search, statistical calculation and figures preparation
42 will be done by SV, NZ, AS, KM. During the study ID, EI, GH, KK, HV, GZ, MT, MS, VH, IO, LC are
43 going to collect the patients.
44
45
46
47

48 **CONFLICT OF INTEREST STATEMENT**

49
50 BK and MGA are employees of Metanomics Health GmbH, Germany.
51

52 The other authors have no competing interest.
53
54
55

56 **Abbreviations:**

57
58 APCI - atmospheric pressure chemical ionization

59
60 AUC – area under the curve

1
2
3 CA 19-9 – carbohydrate antigen 19-9
4
5 CER – ceramides
6
7 DM – diabetes mellitus
8
9 DMC - Data Monitoring Committee
10
11 ERCP – endoscopic retrograde cholangio-pancreatography
12
13 ESI - electrospray ionization
14
15 EUS – endoscopic ultrasound
16
17 FDR - false discovery rate
18
19 GC-MS - gas chromatography-mass spectrometry
20
21 HbA1c – haemoglobin A1c
22
23 HPSG – Hungarian Pancreatic Study Group
24
25 ITAB - International Translational Advisory Board
26
27 LC- MS/MS - liquid chromatography-MS/MS
28
29 MRI – magnetic resonance imaging
30
31 MRM - multiple reaction monitoring
32
33 NPLC - normal phase liquid chromatography
34
35 NPV – negative predictive value
36
37 PaC – pancreatic cancer
38
39 PCA - principal component analysis
40
41 PPV – positive predictive value
42
43 ROC - receiver operating characteristic
44
45 SC - Steering Committee
46
47 SM – sphingomyelins
48
49 SP – Sponsor
50
51 T2DM – type 2 diabetes mellitus
52
53 T3cDM – type 3c diabetes mellitus

54 REFERENCES

- 55 1. National Cancer Institute. SEER Cancer Statistics Review 1975-2006.
- 56 2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world.
57 *HPB (Oxford)* 2008;10:58-62.
- 58 3. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. *Ann*
59 *Oncol* 2013;24:792-800.


- 1
- 2
- 3
- 4 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7–30.
- 5
- 6 5. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and
- 7 Risk Factors. *World J Oncol.* 2019;10(1):10-27.
- 8
- 9 6. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected
- 10 burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014;74:2913-21.
- 11
- 12 7. Gillen S, Schuster T, Meyer ZBC, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a
- 13 systematic review and meta-analysis of response and resection percentages. *PLoS Med* 2010;7(4):
- 14 e1000267.
- 15
- 16 8. Brand RE, Lerch MM, Rubinstein WS et al. Advances in counselling and surveillance patients at risk
- 17 for pancreatic cancer. *Gut* 2007;56:1460-9.
- 18
- 19 9. Chari ST, Leibson CL, de Andrade M, et al. Probability of pancreatic cancer following diabetes:
- 20 population-based study. *Gastroenterology* 2005;129:504-511.
- 21
- 22 10. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II
- 23 diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer* 2005;92(11):2076-83.
- 24
- 25 11. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort
- 26 studies. *Eur. J. Cancer* 2011;47:1928-1937.
- 27
- 28 12. Tsuchiya R, Noda T, Harada N et al. Collective review of small carcinomas of the pancreas. *Ann Surg*
- 29 1986;203:77-81.
- 30
- 31 13. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic
- 32 cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose
- 33 values prior to diagnosis. *Am J Gastroenterol* 2007;102:2157-2163.
- 34
- 35 14. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis
- 36 of pancreatic cancer. *Lancet Oncol* 2009;10:88-95.
- 37
- 38 15. Illés D, Terzin V, Holzinger G et al. New-onset type 2 diabetes mellitus--A high-risk group suitable
- 39 for the screening of pancreatic cancer? *Pancreatol* 2016;16(2):266-71.
- 40
- 41 16. Hart PA, Kamada P, Rabe KG et al. Weight loss precedes cancer-specific symptoms in pancreatic
- 42 cancer-associated diabetes mellitus. *Pancreas* 2011;40(5):768-72.
- 43
- 44 17. Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for
- 45 pancreatic cancer in an asymptomatic population. *J Gastroenterol Hepatol* 2004;19(2):182-6.
- 46
- 47 18. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. *Inhal Toxicol*
- 48 2014;26(13):811-28.
- 49
- 50 19. Rickes S, Unkrodt K, Neye H et al. Differentiation of pancreatic tumours by conventional ultrasound,
- 51 unenhanced and echoenhanced power Doppler sonography. *Scand J Gastroenterol* 2002;37:1313-20.
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

20. Pannala R, Leirness JB, Bamlet WR et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. *Gastroenterology* 2008;134:981-987.
21. Aggarwal G, Ramachandran V, Javeed N et al. Adrenomedullin up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. *Gastroenterology* 2012;143:1510–1517.
22. Munigala S, Singh A, Gelrud A et al. Predictors for Pancreatic Cancer Diagnosis Following New-Onset Diabetes Mellitus. *Clin Transl Gastroenterol* 2015;6:e118.
23. Choe JW, Kim JS, Kim HJ et al. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. *Pancreas* 2016;45:730-4.
24. Muniraj T, Chari ST. Diabetes and pancreatic cancer. *Minerva gastroenterologica e dietologica* 2012;58:331-45.
25. Chari ST, Kelly K, Hollingsworth MA et al. Early detection of sporadic pancreatic cancer: summative review. *Pancreas* 2015;44:693-712.
26. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. *Nat Rev Gastroenterol Hepatol* 2013;10:423-33.
27. Mayerle J, Kalthoff H, Reszka R, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. *Gut* 2018;67(1):128-137.
28. American Diabetes Association: Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. *Diabetes Care* 2018; 41(Supplement 1): S13-S27.
29. Rabinovitz M, Pitlik SD, Leifer M et al. Unintentional weight loss. A retrospective analysis of 154 cases. *Arch Intern Med* 1986;146(1):186-7.
30. Jung K, Reszka R, Kamlage B et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. *Int J Cancer* 2013;133:2914–2924.
31. Christie WW. Rapid separation and quantification of lipid classes by high performance liquid chromatography and mass (light-scattering) detection. *J Lipid Res* 1985;26:507-12.
32. Mutch DM, Fuhrmann JC, Rein D et al. Metabolite Profiling Identifies Candidate Markers Reflecting the Clinical Adaptations Associated with Roux-en-Y Gastric Bypass Surgery. *Plos One* 2009;4(11):e7905.
33. Roessner U, Wagner C, Kopka J et al. Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. *Plant J* 2000;23:131-42.
34. van Ravenzwaay B, Cunha GCP, Leibold E et al. The use of metabolomics for the discovery of new biomarkers of effect. *Toxicology Letters* 2007;172:21-8.

- 1
- 2
- 3 35. Schmidt H, Schmidt R, Geisslinger G. LC-MS/MS-analysis of sphingosine-1-phosphate and related
- 4 compounds in plasma samples. *Prostaglandins & Other Lipid Mediators* 2006;81:162-70.
- 5
- 6 36. Meller S, Meyer HA, Bethan B et al. Integration of tissue metabolomics, transcriptomics and
- 7 immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate
- 8 cancer. *Oncotarget* 2016;7:1421-38.
- 9
- 10
- 11 37. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - A Practical and Powerful Approach
- 12 to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological* 1995;57:289-
- 13 300.
- 14
- 15
- 16 38. Gart JJ, Nam J. Approximate interval estimation of the ratio of binomial parameters: a review and
- 17 corrections for skewness. *Biometrics* 1988;44:323-38.
- 18
- 19
- 20 39. Scherer R, Schaarschmidt F, Prescher S, Priesnitz KU. Simultaneous confidence intervals for
- 21 comparing biodiversity indices estimated from overdispersed count data. *Biometrical Journal*
- 22 2013;55:246-63.
- 23
- 24
- 25 40. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk
- 26 stratification in acute pancreatitis. *J Gastrointestin Liver Dis* 2015;24(2):177–82.
- 27
- 28
- 29 41. Párniczky A, Mosztbacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-
- 30 study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):105–10.
- 31
- 32 42. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis
- 33 (PINEAPPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion*
- 34 2016;93(2):121–6.
- 35
- 36 43. Dubravcsik Z, , Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of acute
- 37 biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective, randomized,
- 38 interventional, controlled trial. *Pancreatology* 2015;15(2):115–23.
- 39
- 40 44. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute
- 41 pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ*
- 42 *Open* 2017;7(9):e015874.
- 43
- 44 45. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management
- 45 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):292–307.
- 46
- 47 46. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines prepared
- 48 by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61.
- 49
- 50 47. Párniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management
- 51 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25.
- 52
- 53 48. Takács T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management guidelines
- 54 prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88.
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1. Flowchart of the study protocol

* weight loss (except at visit0), abdominal pain/discomfort, abnormal laboratory data, unstable glucose metabolism despite the adequate diet and medical treatment and without intercurrent infection (except at visit0)
EUS: endoscopic ultrasound; MRI: magnetic resonance imaging

** Fasted (overnight, at least 8 h) patients' blood samples at room temperature will be drawn into an EDTA tube. Within 2 h after blood draw samples will be at 19-21°C. After centrifugation, the supernatant is carefully removed. After that, the plasma is transferred in 0.5 ml aliquots to tubes and stored at -80°C, in a dedicated freezer (≤6 h from centrifuge to freezer).

BMJ Open

New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES trial): Protocol of a Prospective, Multicentre Observational trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037267.R2
Article Type:	Protocol
Date Submitted by the Author:	29-Jul-2020
Complete List of Authors:	<p>Illés, Dóra; University of Szeged Faculty of Medicine, First Department of Medicine Ivány, Emese ; University of Szeged Faculty of Medicine, First Department of Medicine Holzinger, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Kosár, Klára; University of Szeged Faculty of Medicine, First Department of Medicine Gordian, Adam M.; Metanomics Health GmbH Kamlage, Beate; Metanomics Health GmbH Zsóri, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Tajti, Máté; University of Szeged Faculty of Medicine, First Department of Medicine Svébis, Márk ; Semmelweis University of Medicine, 1. Department of Internal Medicine Horváth, Viktor; Semmelweis University of Medicine, 1. Department of Internal Medicine Oláh, Ilona; Ilona Tóth Outpatient Clinic Márta, Katalin; Institute for Translational Medicine, University of Pécs Medical School, ; János Szentágothai Research Center, University of Pécs, Vánca, Szilárd; Institute for Translational Medicine, University of Pécs Medical School; János Szentágothai Research Center, University of Pécs, Zádori, Noémi; Pecs Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Szentesi, Andrea; Pecs Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group Czakó, Bálint; University of Szeged Faculty of Medicine, Medical School Hegy, Péter; Pecs Tudományegyetem Általános Orvostudományi Kar, Institution for Translational Medicine Czakó, László; University of Szeged, First Department of Medicine</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Gastroenterology and hepatology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Pancreatic disease < GASTROENTEROLOGY, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 ***New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES trial):***
7 ***Protocol of a Prospective, Multicentre Observational trial***
8
9
10
11
12

13 Dóra Illés¹, Emese Ivány¹, Gábor Holzinger¹, Klára Kosár¹, M. Gordian Adam², Beate Kamlage², Gábor
14 Zsóri¹, Máté Tajti¹, Márk Svébis³, Viktor Horváth³, Ilona Oláh⁴, Katalin Márta⁵, Szilárd Vánca⁵, Noémi
15 Zádori⁵, Andrea Szentesi⁶, Bálint Czakó⁷, Péter Hegyi^{5,6}, László Czakó¹
16
17
18
19
20
21
22
23
24
25
26

27 ¹First Department of Medicine University of Szeged, Szeged, HU

28 ²Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany

29 ³ First Department of Medicine University of Semmelweis, Budapest, HU

30 ⁴Ilona Tóth Outpatient Clinic, Diabetes Care, Budapest, HU

31 ⁵Insitute for Translational Medicine, Medical School, University of Pécs Medical School, Pécs, HU

32 ⁶Insitute for Translational Medicine, University of Szeged Medical School, Szeged, HU

33 ⁷University of Szeged Medical School, Szeged, HU
34
35
36
37
38
39
40

41 Key words: new-onset diabetes mellitus, pancreatic cancer, biomarker, screening
42
43

44 **Correspondence to:**

45 László Czakó, MD, PhD, DSc

46 First Department of Medicine,

47 University of Szeged,

48 Szeged, P.O.Box: 427, H-6701, Hungary

49 E-mail: czako.laszlo@med.u-szeged.hu

50 Telephone: +36-62-545187, Fax: +36-62-545185
51
52
53
54
55
56
57

58 Word count: 3922
59
60

ABSTRACT

Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with an overall 5-year survival of approximately 8%. The success in reducing the mortality rate of PDAC is related not only to the discovery of new therapeutic agents, but also to a significant extent to the development of early detection and prevention programs. Patients with new-onset diabetes mellitus represent a high-risk group for PDAC as they have an 8-fold higher risk of PDAC than the general population. The proposed screening program may allow the detection of PDAC in the early, operable stage. Diagnosing more patients in the curable stage might decrease the morbidity and mortality rates of PDAC and additionally reduce the burden of the healthcare.

Methods & Analysis: This is a prospective, multicentre observational cohort study. Patients ≥ 60 years old diagnosed with new-onset (≤ 6 months) diabetes will be included. Exclusion criteria are (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; (5) present malignant disease and (6) type-1 diabetes mellitus. Follow up visits are scheduled every 6 months for up to 36 months. Data collection is based on questionnaires. Clinical symptoms, body weight and fasting blood will be collected at each, CA 19-9 and blood to biobank at every second visit. The blood samples will be processed to plasma and analysed with mass spectrometry-based metabolomics. The metabolomic data will be used for biomarker validation for early detection of PDAC in the high-risk group new-onset diabetes patients. Patients with worrisome features will undergo MRI or EUS investigation, and surgical referral depending on the radiological findings. The primary endpoint is the incidence of PDAC in patients with newly diagnosed diabetes mellitus.

Ethics and dissemination: the study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (41085-6/2019). We plan to disseminate the results to several members of the healthcare system including medical doctors, dietitians, nurses, patients etc. We plan to publish the results in a peer-reviewed high quality journal for professionals. In addition, we also plan to publish it for lay readers in order to maximize the dissemination and benefits of this trial.

Trial registration: The trial has been registered at the ClinicalTrials.gov (NCT04164602).

Strengths and limitations of this study:

Strength 1: As patients are included prospectively, the study will yield a cohort to examine the metabolic changes that coincide with the occurrence of PDAC at a very early stage before it is diagnosed.

Strength 2: The criteria for the diagnoses of diabetes and PDAC will be uniformly applied throughout the study period, moreover the diagnosis of pancreatic cancer will be confirmed with a high level of certainty in all subjects.

Strength 3: Taking part in the screening is connected to a very low burden, as the blood collection is only minimally invasive.

Strength 4: All patients will be monitored closely and frequently, which will increase the survival of all participants, especially the high-risk patients.

Limitation 1: It might be really difficult to include the required number of patients, considering that PDAC is a rare disease, and the elderly population has more comorbidities which not even make our observation more difficult, but also leads to a higher follow-up loss during the 36 months.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is a rare disease with a lifetime prevalence of 1.39%, but its prevalence is continuously increasing (1-3). The prognosis is extremely poor: it has a five-year survival rate of only 7-8% (4), and this rate has barely improved in the last 40 years (5). PDAC will be the second leading cause of cancer-related death by 2030 (6). The high mortality rate is a consequence of delayed diagnosis: in the absence of specific symptoms, PDAC is often diagnosed at an advanced stage. Surgery is the only curative treatment at this moment. Unfortunately, only 20% of the patients are eligible for curative resection at the time of the diagnosis because of the presence of metastases and locoregional infiltration (7). The success in reducing the mortality rate of PDAC is related to a significant extent to the development of early detection and prevention programs. An effective screening programme is needed for the early diagnosis of PDAC in the asymptomatic stage to improve the prognosis. Due to the low lifetime prevalence, the population-based screening is neither feasible nor cost-effective. It is recommended that subjects at high risk of PDAC should be screened (8).

Pancreatic ductal adenocarcinoma and diabetes mellitus

Patients with diabetes mellitus (DM) have an eight-fold higher risk of developing PDAC within 2–3 years after the diagnosis of diabetes relative to the general population (9). In a meta-analysis which included 36

1
2
3 studies, individuals in whom DM had only recently been diagnosed (<4 years) had a 50% increased risk
4 of PDAC as compared with individuals who had diabetes for >5 years (10). Another meta-analysis of 35
5 cohort studies showed that DM was associated with an increased risk of PDAC (summary relative risks
6 (RRs)=1.94; 95% CI, 1.66–2.27). Interestingly, the risk decreased with the duration of diabetes (5.38 for
7 <1 year, 1.95 for 1–4 years, and 1.49 for 5–9 years, 1.47 for ≥ 10 years), thus providing evidence that
8 diabetes in PDAC patients is caused by the cancer itself (11). In these cases, patients are actually
9 suffering from diabetes type 3c (T3cDM). Diabetes is already prevalent in small PDACs (12), and what is
10 more important, that diabetes occurs before the tumour is radiologically detectable (13). A population-
11 based study found that approximately 1% of patients with new-onset diabetes at age 50 or older will be
12 diagnosed with PDAC within 3 years of first meeting criteria for diabetes, and 56% of these within 6
13 months of meeting the criteria for diabetes (9). Recognition of new-onset diabetes as an early
14 manifestation of PDAC could lead to diagnosis of asymptomatic, early-stage PDAC (14). In our recent
15 prospective study, the prevalence of PDAC in patients with new-onset diabetes was significantly higher
16 than in the general population (the value of the Standardised Incidence Ratio for PDAC in new-onset type
17 2 diabetic patients was 198.6 (95% CI = 6.25-46.9)); therefore, screening seems to be beneficial for
18 detecting PDAC in this patient population (15). Weight loss in patients with pancreatic carcinoma-
19 associated DM often precedes the onset of diabetes, while new-onset primary type 2 DM is typically
20 associated with weight gain (16). The paradoxical development of diabetes in the face of ongoing weight
21 loss may be an important clue to diagnose PDAC in patients with new onset of diabetes.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Screening modalities**

38
39
40
41 The carbohydrate antigen 19-9 (CA19-9) is currently the only blood-based biomarker in clinical use for
42 PDAC. The sensitivity of this marker for PDAC is 75%, the specificity is 90%, the positive predictive
43 value is 69%, and the negative predictive value is 90% (17). These values fall below the required
44 characteristics of a reliable screening test (10, 18); therefore, serum CA19-9 measurement is not suitable
45 for screening for PDAC. Imaging modalities represent the gold standard for diagnosing PDAC. The first
46 choice is transabdominal ultrasound. The sensitivity of transabdominal ultrasonography in PDAC
47 diagnosis is only 50–70%. Its accuracy is low in tumours <1 cm, which are usually operable and
48 negatively influenced by obesity and meteorism (19). Computer tomography has a better accuracy in
49 diagnosing PDAC; however, the low prevalence of PDAC and radiation exposure associated with the
50 modality prevents it from being used as a screening test. The odds for a correct diagnosis are also high
51 employing endoscopic ultrasound or endoscopic retrograde cholangiopancreatography (ERCP), but again
52 the low prevalence of PDAC in combination with the burden of the endoscopic intervention to the patient
53
54
55
56
57
58
59
60

preclude the application of these diagnostic methods for screening. Furthermore, it is not economically feasible to employ computer tomography or endoscopic imaging for screening as these methods are associated with high costs to the healthcare system.

The success of the strategy of using new-onset diabetes as a screening tool to identify subjects with a high likelihood of having asymptomatic PDAC will depend on our ability to differentiate PDAC-associated diabetes from the more common type 2 diabetes. PDAC-induced diabetes is thought to be a paraneoplastic phenomenon involving the release of products from the tumour rather than a result of the destruction of the pancreas due to malignant infiltration (20, 21). Data on incidence of PDAC in new onset of DM is rare, numbers of 0.25% (22), 0.85% (9), and 3.6% (23) have been reported. Therefore, to enable a diagnostic follow-up of new onset of diabetes, a further enrichment of this group is needed (14, 24, 25), e.g. elderly subjects (age is an independent risk factor for PDAC), weight loss (26), or smoking.

A biomarker panel consisting of nine metabolites plus the established protein CA19-9 were recently identified by Mayerle and colleagues with 89.9% sensitivity, 91.3% specificity and 99.8% negative predictive value for differentiating PDAC from chronic pancreatitis (27). Employing the same methods, a biomarker panel for differential diagnosis between PDAC and non-cancer-related diabetes was identified. The metabolite signature needs validation in an independent test cohort, which will be enabled with the present study. Provided the biomarker is validated, the panel could be effective for screening of the high-risk group patients diagnosed with new-onset DM.

Aims of the project

- a) Estimate the incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes
- b) Diagnose pancreatic ductal adenocarcinoma in an early operable stage
- c) Validate a biomarker that distinguishes patients with PDAC-caused T3cDM from patients with T2DM.

METHODS AND ANALYSIS

Design

This is a prospective, multicentre, observational cohort study aiming to validate a biomarker panel in the early stage of PDAC. The data collection is based on questionnaires and blood samples will be drawn from all patients. The questionnaires (Form A at recruitment, Form B at every follow up visit) will be filled by every included patients.

Parameter	Value and unit	Description
Fasting plasma glucose	≥ 126 mg/dL (7.0 mmol/L)	Fasting is defined as no caloric intake for at least 8 h.
2 h plasma glucose	≥ 200 mg/dL (11.1 mmol/L)	Oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
HbA1c	$\geq 6.5\%$ (48 mmol/mol)	The test should be performed in a laboratory using a method that is NGSP certified and standardised to the DCCT assay.

Table 1. Diagnostic criteria of diabetes mellitus.

The inclusion criteria of this study are the following: (1) patients over 60 years of age; (2) diabetes diagnosed within six months (newly diagnosed) - diagnostic criteria are based on the Diabetes Control and Complications Trial (Table 1. (28)); (3) signed written informed consent.

Exclusion criteria are as follows: (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; (5) present malignant disease; and (6) type-1 diabetes mellitus. Patients with chronic pancreatitis were excluded because a metabolic signature differentiating between chronic pancreatitis and PDAC patients has already been published (27) and is currently further evaluated by the META-PAC consortium, while the present study aims to differentiate between patients with PDAC-caused new onset diabetes and new onset diabetes due to other causes.

Sample size

Mayerle et al. found that the biomarker signature in question could distinguish patients with PDAC from those without with an 89.9% sensitivity (marginal error 8.9%) and 81.3% specificity (marginal error 10.3%)(27). Chari et al. concluded that elderly subjects with new-onset DM has 8 times higher risk for pancreatic cancer than for a person of similar age and sex without DM (9), and also considering the epidemiologic data suggest that in Hungary the prevalence of PDAC is considerably higher than that compared to other countries' (29), we assumed a 4% prevalence for PDAC. In reference to these data, sample size calculation suggests that 1241 patients will need to be enrolled in order to confirm or reject the hypothesis for the primary endpoint with a 10% dropout, 80% power and 95% significance level. The recruitment period is planned to last 36 months, and all included patients will be followed for 36 months.

Duration:

1
2
3 The first recruiting centre will be initialized in 1 July 2019. Start of the patient recruitment: January 31,
4 2020. Planned finish of the study-recruitment: January 30, 2023.

6 **Clinical data and clinical endpoints:**

8 Essential baseline clinical data: age, sex, body weight, BMI, date of DM diagnosis, date of sampling,
9 comorbidities, antidiabetic medication, clinical symptoms, histology and stage of PDAC.

13 Primary clinical endpoints: the sensitivity, specificity, positive and negative predictive values, and
14 accuracy of the biomarker test

17 Secondary endpoints:

18 (1) mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients; (2) the proportion of
19 localised and resectable pancreatic ductal adenocarcinoma; (3) change in body weight before Visit 1 and
20 during Visit 2-6; (4) change in fasting blood glucose and HbA1c before Visit 1 and during Visit 2-6; (5)
21 antidiabetic medications and the risk of pancreatic ductal adenocarcinoma; (6) presence of concomitant
22 diseases; (7) smoking and alcohol intake; (8) incidence of pancreatic ductal adenocarcinoma in patients
23 with new-onset diabetes; (9) cost-benefit analysis.

31 **Study protocol:**

32 Diabetic patients will be recruited by our diabetologist and collaborating family physicians based on a
33 recent (< 6 months) laboratory test (Table 1). Visit 0 is scheduled within 2 weeks from the referral
34 (Figure 1). Patients who meet study entry criteria and no exclusion, will be informed and offered to
35 participate in the study, however signed informed consent will be necessary for inclusion. Clinical data,
36 body weight and worrisome features (unintentional weight loss: 5% of body weight within 6 months
37 without knowing the reason (30), abdominal pain/discomfort, abnormal laboratory data, unstable glucose
38 metabolism despite the adequate diet and medical treatment and without intercurrent infection) will be
39 recorded at Visit 0, and a fasting blood sample will be taken for assessment of laboratory data and
40 metabolomics. C-peptide and glutamic acid decarboxylase antibodies (GADA) will be determined to
41 classify diabetes at Visit 0. Patients with type-1 diabetes mellitus will be excluded. If worrisome features
42 are present at Visit 0, MRI or EUS is performed. Unambiguous PaC lesions (>1 cm or seen also by
43 magnetic resonance imaging) will be referred to surgery for resection. In case of ambiguous lesions in the
44 pancreas, EUS-fine needle aspiration will be performed. Visit 1-5 are scheduled every 6 months. Clinical
45 symptoms, body weight, laboratory data (fasting blood glucose, HbA1c, liver and renal function, lipids,
46 blood count) will be collected at each visit. Blood to biobank and CA 19-9 will be taken at every 12
47 months. The follow-up will be closed at 36 months.

Biochemical methods

After informed consent, fasted (overnight, at least 8 h) patients' blood samples will be drawn into an EDTA tube. 9 ml blood tubes are centrifuged within 2 h after blood draw using a swing-out rotor at 2000 xg for 10 minutes. The sample processing is done at room temperature and the centrifuge is temperature-controlled at 19-21°C. After centrifugation, the supernatant is carefully removed, transferred to a fresh 9 ml tube and gently mixed in order to homogenise any gradient that might have been generated in the plasma supernatant. After that, the plasma is transferred in 0.5 ml aliquots to tubes (either Eppendorf Safe-Lock-Tubes 2 ml or Sarstedt Screw cap micro tubes 2 ml) and stored at -80°C, in a dedicated freezer (≤ 6 h from centrifuge to freezer). Biomarkers will be determined comparing metabolite levels in plasma samples from patients diagnosed with PDAC and diabetic cancer-free patients (26). CA19-9 determination is performed centralised at a certified clinical laboratory applying a cut-off of 37 U/ml as a classifier.

Cost of the biomarker test, quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) will be determined.

Metabolite profiling:

MxP® Global Profiling:

Two types of mass spectrometry analyses are applied. GC-MS (gas chromatography-mass spectrometry; Agilent 6890 GC coupled to an Agilent 5973 MS System, Agilent, Waldbronn, Germany) and LC-MS/MS (liquid chromatography-MS/MS; Agilent 1100 HPLC-System, Agilent, Waldbronn, Germany, coupled to an Applied Biosystems API4000 MS/MS-System, Applied Biosystems, Darmstadt, Germany) are used for a metabolite profiling approach (31). Fractionation and derivatisation of samples and detection technologies have been previously described (32-35). Proteins are removed from plasma samples (60 μ l) by precipitation. Subsequently, polar and non-polar fractions are separated for both GC-MS and LC-MS/MS analyses by adding water and a mixture of ethanol and dichloromethane. For GC-MS analyses, the non-polar fraction is treated with methanol under acidic conditions to yield the fatty acid methyl esters derived from both free fatty acids and hydrolysed complex lipids. The polar and non-polar fractions are further derivatised with O-methyl-hydroxylamine hydrochloride (20 mg/ml in pyridine) to convert oxo-groups to O-methyloximes and subsequently with a silylating agent (N-Methyl-N-(trimethylsilyl) trifluoroacetamide) before GC-MS analysis. For LC-MS/MS analyses, both fractions are dried and subsequently reconstituted in appropriate solvent mixtures. HPLC (High performance LC) is performed by gradient elution using methanol/water/formic acid on reversed phase separation columns.

MxP® Lipids:

MxP[®] Lipids covers profiling of sphingolipids (ceramides, sphingomyelins, and sphingobases). The metabolites are analysed in a semi-quantitative approach (i.e. relative to a pool). Total lipids are extracted from plasma by liquid/liquid extraction using chloroform/methanol. The lipid extracts are subsequently fractionated by normal phase liquid chromatography (NPLC) into different lipid groups according to (32, 36). The fractions are analysed by LC-MS/MS using electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) with detection of specific multiple reaction monitoring (MRM) transitions for sphingomyelins (SM) and ceramides (CER) respectively.

Data normalization

Details of data normalization have been published (27). Metabolite profiling based on a semi-quantitative analytical platform results in relative metabolite levels (“ratio”) to a defined reference. To support this concept and to allow an alignment of different analytical batches, two different reference sample types are run in parallel throughout the whole process. First, a project pool is generated from aliquots of all samples and measured with four replicates within each analytical sequence that comprised 24 samples. For all semi-quantitatively analysed metabolites, the results of each analyte from each sample are normalised against the median of the corresponding analyte in the pool reference samples within each analytical sequence to provide pool-normalised ratios. This process step compensates for inter- and intra-instrumental variation, i.e. variability that occurs when different analytical sequences are analysed by different devices. Second, to allow for an experiment-to-experiment alignment of semi-quantitative data, MxPool[™] (a large pool of a commercial human EDTA plasma suited for alignment of MxP[®] studies) is analysed with 12 replicated samples, and the pool-normalised ratios are further normalised to the median of the MxPool[™] samples, i.e. ratios from this study are on the same level and therefore comparable with data from other studies normalised to other aliquots of the same MxPool[™]. A rigorous quality control is performed on peak, analyte and sample level and has been described previously (37).

Data collection and follow-up

Data collection is based on questionnaires, and will be stored in a personalised electronic database (eCRF). Form A: contains all antropometric parameters, routine clinical chemistry tests, fasting blood glucose and HbA1c. Follow-up visits will be scheduled by the patient registration system every 6 months. Blood will be taken for biomarker identification with metabolomics and CA19-9 determination at every 12 months. The total follow-up period is three years.

Pancreas adenocarcinoma will be diagnosed by histological examination.

Data set analysis and normalization

1
2
3 Descriptive statistics – mean, median, standard deviation, quartiles and relative frequency –relative risk
4 (dichotomous variables), Independent Two-sample T test (continuous variable) in the case of normal
5 distribution, furthermore Mann-Whitney test in lack of normal distribution will be performed. Logistic
6 regression will be applied for the exploring of predictive factors. Affiliated statistical analyses will be
7 performed with an error probability of 0.05 (type-I error probability).
8

9
10
11 Prior to statistical analysis, log₁₀ transformation of ratios is conducted so that the data distribution
12 becomes approximately normal. SIMCA-P version 14.0 (Umetrics AB, Umea, Sweden), TIBCO®
13 Spotfire® 7.12.0 and R 3.3.4 are used for data analyses and visualizations. Initially, an exploratory
14 multivariate analysis (Principal Component Analysis, PCA) is applied to log₁₀-transformed ratios scaled
15 to unit variance.
16

17
18
19 A simple linear model (ANOVA, package nlme) addressing additional clinical information and
20 potentially confounding factors such as “disease”, “age”, “body mass index”, “gender” and “sample
21 storage time” as fixed effects is fitted to the data. Significance level is set to 5%. The multiple test
22 problem for the number of metabolites is addressed by calculating the false discovery rate (FDR) using
23 the Benjamini & Hochberg method (38).
24

25
26
27 To classify patients depending on their metabolic profiles a penalised logistic regression is fitted via
28 Elastic Net Algorithm using the R package glmnet (38). Equal penalties are used for both the L1 and the
29 L2 norm. Afterwards the cutoff established previously on the biomarker identification dataset is applied
30 on the test data without retraining, and the performance is measured in terms of area under the curve
31 (AUC), sensitivity and specificity. Confidence levels for the AUC are calculated using the binormal
32 model for the receiver operating characteristic (ROC) curve. When the sensitivity is fixed at a particular
33 value, the positive and negative predictive values (PPV, NPV) and the accuracy become monotone
34 functions of the specificity; and confidence intervals for these estimates are obtained by transformation of
35 the confidence interval for the specificity. Confidence intervals for sensitivity, specificity and accuracy
36 are obtained for the cutoff pre-specified in the training data by the method of Clopper and Pearson for the
37 binomial distribution. For PPV and NPV the confidence intervals will be obtained by the method of Gart
38 and Nam (39) for ratios of binomial parameters as implemented in the R package pairwise CI (40). When
39 comparing the biomarker and CA19-9 on the test data, differences in sensitivity and specificity will be
40 tested for with the McNemar test.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Centres**

55
56 The study will start with the following centres (University of Szeged, University of Pécs, University of
57 Semmelweis), however, other centres are welcome to participate as an open label study. Completion of
58 the LETTER OF INTENT form will be mandatory for registering the participation of each institution.
59
60

PATIENT AND PUBLIC INVOLVEMENT

The scientific protocol can only be done in one way, leaving little room for public involvement in the design, therefore the patients have not been involved in the design and conception of this study.

ETHICS AND DISSEMINATION

Trial registration: The trial has been registered at the ClinicalTrials.gov (NCT04164602)

Ethical approval: the study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (41085-6/2019). Protocol Version: V1.0 08.01.2019.

Publication policy

Centres providing more than 50 patients can provide author to the authorship list.

Dissemination policy

We plan to disseminate the results to several members of the healthcare system including medical doctors, dietitians, nurses, patients etc. We plan to publish the results in a peer-reviewed high quality journal for professionals. In addition, we also plan to publish it for lay readers in order to maximize the dissemination and benefits of this trial.

DISCUSSION

PDAC has a dismal prognosis, which is due to its late diagnosis. The success in reducing the mortality rate of PDAC is related to the development of early detection and prevention programs. Age and DM are known as risk factors of PDAC (9-11, 14, 15).

The expected positive endpoint of this study is to validate a biomarker panel in elderly patients diagnosed with diabetes; whether it is suitable for early stage diagnosis of a mostly incurable, high-mortality cancer, when surgery is still possible and the cancer can be cured. PDAC-induced diabetes belongs to the group T3cDM and in parallel, T3cDM means the highest-high risk group for PDAC. Unfortunately, it is still underdiagnosed in the clinical practice – maybe because its symptoms are very similar to T2DM's and its diagnosis is based on complex, expensive tests that are not routinely available (41). To diagnose T3cDM patients based on these criteria would lead to enormous difficulties and it would not be a cost-effective screening method, which is unfavorable. While there are several pancreatic diseases that can cause T3cDM, this study focuses on the differences between PDAC-T3cDM and T2DM only. In that manner, this biomarker panel could be a diagnostic tool for the T3cDM-subgroup PDAC-T3cDM. The test only requires one blood sample collection, which means that it is simple, repeatable, tolerable, minimally invasive, nearly painless, widely achievable and relatively cheap – it fulfils all the criteria set for a screening method. Identifying PDAC in an earlier (still resectable) stage through surveillance of high-risk

1
2
3 patients would increase surgical resection rate, cure rates and survival by 30–40%. It would save lives,
4 maintain better well-being among the population and would have an enormous financial benefit: the
5 increasing number of successful surgical interventions leads to a lower necessity of chemotherapy and
6 palliative interventions (such as stent implantations or gastroenteroanastomosis operations), moreover
7 lower the burden the healthcare cost.
8
9
10
11
12

13 **Trial organization, committees and boards:** The coordinator of the NODES study is LC with the
14 support of the Hungarian Pancreatic Study Group (HPSG-coordinating society, [https://tm-](https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/)
15 [centre.org/en/study-groups/hungarian-pancreatic-study-group/](https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/)). HPSG has been running high-quality
16 international, multicentre clinical trials since 2014 and has published the relevant guidelines for
17 pancreatic diseases to improve patient care in pancreatology (42-50).
18
19
20
21
22

23 The trial will be supported by the following committees:

24
25 Steering Committee (SC): This committee will be led by PH (gastroenterologist and internal medicine
26 specialist). The members in Szeged (HU) will be: DI, EI.
27
28
29

30
31 International Translational Advisory Board (ITAB): This board will involve gastroenterologists. The
32 ITAB will regularly monitor the progression of the trial and might give recommendations to the SC.
33
34

35 Data Monitoring Committee (DMC): DMC will handle all the data and ensure that the data in the eCRF is
36 accurate, complete and legible. Data Management Plan (DMP) will describe the detailed data flow. The
37 Data Manager will validate the data from completed eCRFs, according to a Data Cleaning Plan (DCP).
38 Any missing, implausible or inconsistent recordings in the eCRFs will be referred back to the Investigator
39 using a data query form (DQF), and be documented for each individual subject before clean file status is
40 declared. All changes to eCRFs will be recorded.
41
42
43
44
45

46 ACKNOWLEDGEMENTS

47 **Funding**

48 The study was supported by National Research, Development and Innovation Office grants (K128222 to
49 LC). Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical
50 School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic
51 Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the
52 National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-
53 125678 and EFOP 3.6.2-16-2017-00006 Live Longer).
54
55
56
57
58
59
60

Authors' contributions

The study was designed by ID, LC, BK. ID, LC, MGA drafted the manuscript. All authors edited, read and approved the final manuscript. Literature search, statistical calculation and figures preparation will be done by SV, NZ, AS, BC, KM. Steering Committee will be led by PH. During the study ID, EI, GH, KK, IO, GZ, MT, MS, VH, LC are going to collect the patients.

CONFLICT OF INTEREST STATEMENT

BK and MGA are employees of Metanomics Health GmbH, Germany.

The other authors have no competing interest.

Abbreviations:

APCI - atmospheric pressure chemical ionization

AUC – area under the curve

CA 19-9 – carbohydrate antigen 19-9

CER – ceramides

DM – diabetes mellitus

DMC - Data Monitoring Committee

ERCP – endoscopic retrograde cholangio-pancreatography

ESI - electrospray ionization

EUS – endoscopic ultrasound

FDR - false discovery rate

GC-MS - gas chromatography-mass spectrometry

HbA1c – haemoglobin A1c

HPSG – Hungarian Pancreatic Study Group

ITAB - International Translational Advisory Board

LC- MS/MS - liquid chromatography-MS/MS

MRI – magnetic resonance imaging

MRM - multiple reaction monitoring

NPLC - normal phase liquid chromatography

NPV – negative predictive value

PaC – pancreatic cancer

PCA - principal component analysis

PPV – positive predictive value

1
2
3 ROC - receiver operating characteristic

4
5 SC - Steering Committee

6
7 SM – sphingomyelins

8
9 SP – Sponsor

10
11 T2DM – type 2 diabetes mellitus

12
13 T3cDM – type 3c diabetes mellitus


14 15 REFERENCES

- 16
17
18 1. National Cancer Institute. SEER Cancer Statistics Review 1975-2006.
- 19
20 2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the
21 world. *HPB (Oxford)* 2008;10:58-62.
- 22
23 3. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. *Ann*
24 *Oncol* 2013;24:792-800.
- 25
26 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7–30.
- 27
28 5. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and
29 Risk Factors. *World J Oncol.* 2019;10(1):10-27.
- 30
31 6. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the
32 unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res*
33 2014;74:2913-21.
- 34
35 7. Gillen S, Schuster T, Meyer ZBC, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a
36 systematic review and meta-analysis of response and resection percentages. *PLoS Med* 2010;7(4):
37 e1000267.
- 38
39 8. Brand RE, Lerch MM, Rubinstein WS et al. Advances in counselling and surveillance patients at risk
40 for pancreatic cancer. *Gut* 2007;56:1460-9.
- 41
42 9. Chari ST, Leibson CL, de Andrade M, et al. Probability of pancreatic cancer following diabetes:
43 population-based study. *Gastroenterology* 2005;129:504-511.
- 44
45 10. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II
46 diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer* 2005;92(11):2076-83.
- 47
48 11. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort
49 studies. *Eur. J. Cancer* 2011;47:1928-1937.
- 50
51 12. Tsuchiya R, Noda T, Harada N et al. Collective review of small carcinomas of the pancreas. *Ann*
52 *Surg* 1986;203:77-81.

13. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. *Am J Gastroenterol* 2007;102:2157-2163.
14. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. *Lancet Oncol* 2009;10:88-95.
15. Illés D, Terzin V, Holzinger G et al. New-onset type 2 diabetes mellitus--A high-risk group suitable for the screening of pancreatic cancer? *Pancreatol* 2016;16(2):266-71.
16. Hart PA, Kamada P, Rabe KG et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. *Pancreas* 2011;40(5):768-72.
17. Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. *J Gastroenterol Hepatol* 2004;19(2):182-6.
18. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. *Inhal Toxicol* 2014;26(13):811-28.
19. Rickes S, Unkrodt K, Neye H et al. Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echoenhanced power Doppler sonography. *Scand J Gastroenterol* 2002;37:1313-20.
20. Pannala R, Leirness JB, Bamlet WR et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. *Gastroenterology* 2008;134:981-987.
21. Aggarwal G, Ramachandran V, Javeed N et al. Adrenomedullin up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. *Gastroenterology* 2012;143:1510-1517.
22. Munigala S, Singh A, Gelrud A et al. Predictors for Pancreatic Cancer Diagnosis Following New-Onset Diabetes Mellitus. *Clin Transl Gastroenterol* 2015;6:e118.
23. Choe JW, Kim JS, Kim HJ et al. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. *Pancreas* 2016;45:730-4.
24. Muniraj T, Chari ST. Diabetes and pancreatic cancer. *Minerva gastroenterologica e dietologica* 2012;58:331-45.
25. Chari ST, Kelly K, Hollingsworth MA et al. Early detection of sporadic pancreatic cancer: summative review. *Pancreas* 2015;44:693-712.
26. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. *Nat Rev Gastroenterol Hepatol* 2013;10:423-33.
27. Mayerle J, Kalthoff H, Reszka R, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. *Gut* 2018;67(1):128-137.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
28. American Diabetes Association: Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. *Diabetes Care* 2018; 41(Supplement 1): S13-S27.
29. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J Oncol.* 2019;10(1):10-27
30. Rabinovitz M, Pitlik SD, Leifer M et al. Unintentional weight loss. A retrospective analysis of 154 cases. *Arch Intern Med* 1986;146(1):186-7.
31. Jung K, Reszka R, Kamlage B et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. *Int J Cancer* 2013;133:2914–2924.
32. Christie WW. Rapid separation and quantification of lipid classes by high performance liquid chromatography and mass (light-scattering) detection. *J Lipid Res* 1985;26:507-12.
33. Mutch DM, Fuhrmann JC, Rein D et al. Metabolite Profiling Identifies Candidate Markers Reflecting the Clinical Adaptations Associated with Roux-en-Y Gastric Bypass Surgery. *Plos One* 2009;4(11):e7905.
34. Roessner U, Wagner C, Kopka J et al. Technical advance: simultaneous analysis of metabolites in potato tuber by gas chromatography-mass spectrometry. *Plant J* 2000;23:131-42.
35. van Ravenzwaay B, Cunha GCP, Leibold E et al. The use of metabolomics for the discovery of new biomarkers of effect. *Toxicology Letters* 2007;172:21-8.
36. Schmidt H, Schmidt R, Geisslinger G. LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. *Prostaglandins & Other Lipid Mediators* 2006;81:162-70.
37. Meller S, Meyer HA, Bethan B et al. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer. *Oncotarget* 2016;7:1421-38.
38. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological* 1995;57:289-300.
39. Gart JJ, Nam J. Approximate interval estimation of the ratio of binomial parameters: a review and corrections for skewness. *Biometrics* 1988;44:323-38.
40. Scherer R, Schaarschmidt F, Prescher S, Priesnitz KU. Simultaneous confidence intervals for comparing biodiversity indices estimated from overdispersed count data. *Biometrical Journal* 2013;55:246-63.
41. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (type 3c)—are we neglecting an important disease? *Eur J Intern Med* 2013;24:203–206.
42. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk stratification in acute pancreatitis. *J Gastrointestin Liver Dis* 2015;24(2):177–82.

- 1
2
3 43. Párniczky A, Mosztbacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-
4 study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):105–10.
5
6 44. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis
7 (PINEAPPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion*
8 2016;93(2):121–6.
9
10 45. Dubravcsik Z, , Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of
11 acute biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective,
12 randomized, interventional, controlled trial. *Pancreatology* 2015;15(2):115–23.
13
14 46. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute
15 pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ*
16 *Open* 2017;7(9):e015874.
17
18 47. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management
19 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):292–
20 307.
21
22 48. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines
23 prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61.
24
25 49. Párniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management
26 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25.
27
28 50. Takács T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management
29 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Flowchart of the study protocol

* weight loss (except at visit0), abdominal pain/discomfort, abnormal laboratory data, unstable glucose metabolism despite the adequate diet and medical treatment and without intercurrent infection (except at visit0)
EUS: endoscopic ultrasound; MRI: magnetic resonance imaging

** Fasted (overnight, at least 8 h) patients' blood samples at room temperature will be drawn into an EDTA tube. Within 2 h after blood draw samples will be at 19-21°C. After centrifugation, the supernatant is carefully removed. After that, the plasma is transferred in 0.5 ml aliquots to tubes and stored at -80°C, in a dedicated freezer (≤6 h from centrifuge to freezer).

BMJ Open

New Onset of Diabetes in a Association with pancreatic ductal adenocarcinoma (NODES trial): Protocol of a Prospective, Multicentre Observational trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037267.R3
Article Type:	Protocol
Date Submitted by the Author:	05-Sep-2020
Complete List of Authors:	<p>Illés, Dóra; University of Szeged Faculty of Medicine, First Department of Medicine Ivány, Emese ; University of Szeged Faculty of Medicine, First Department of Medicine Holzinger, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Kosár, Klára; University of Szeged Faculty of Medicine, First Department of Medicine Gordian, Adam M.; Metanomics Health GmbH Kamlage, Beate; Metanomics Health GmbH Zsóri, Gábor; University of Szeged Faculty of Medicine, First Department of Medicine Tajti, Máté; University of Szeged Faculty of Medicine, First Department of Medicine Svébis, Márk ; Semmelweis University of Medicine, 1. Department of Internal Medicine Horváth, Viktor; Semmelweis University of Medicine, 1. Department of Internal Medicine Oláh, Ilona; Ilona Tóth Outpatient Clinic Márta, Katalin; Institute for Translational Medicine, University of Pécs Medical School, ; János Szentágothai Research Center, University of Pécs, Vánca, Szilárd; Institute for Translational Medicine, University of Pécs Medical School; János Szentágothai Research Center, University of Pécs, Zádori, Noémi; Pécsi Tudományegyetem Általános Orvostudományi Kar, Institute for Translational Medicine Szentesi, Andrea; Pécsi Tudományegyetem, Institute for Translational Medicine; Szegedi Tudományegyetem, MTA-SZTE Translational Gastroenterology Research Group Czakó, Bálint; University of Szeged Faculty of Medicine, Medical School Hegy, Péter; Pécsi Tudományegyetem Általános Orvostudományi Kar, Institution for Translational Medicine Czakó, László; University of Szeged, First Department of Medicine</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Gastroenterology and hepatology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Pancreatic disease < GASTROENTEROLOGY, PREVENTIVE MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 ***New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES trial):***
7 ***Protocol of a Prospective, Multicentre Observational trial***
8
9
10
11
12

13 Dóra Illés¹, Emese Ivány¹, Gábor Holzinger¹, Klára Kosár¹, M. Gordian Adam², Beate Kamlage², Gábor
14 Zsóri¹, Máté Tajti¹, Márk M. Svébis³, Viktor Horváth³, Ilona Oláh⁴, Katalin Márta⁵, Szilárd Vánca⁵,
15 Noémi Zádori⁵, Andrea Szentesi⁶, Bálint Czakó⁷, Péter Hegyi^{5,6}, László Czakó¹
16
17
18
19
20
21
22
23
24
25
26

27 ¹First Department of Medicine University of Szeged, Szeged, HU

28 ²Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany

29 ³ First Department of Medicine University of Semmelweis, Budapest, HU

30 ⁴Ilona Tóth Outpatient Clinic, Diabetes Care, Budapest, HU

31 ⁵Insitute for Translational Medicine, Medical School, University of Pécs Medical School, Pécs, HU

32 ⁶Insitute for Translational Medicine, University of Szeged Medical School, Szeged, HU

33 ⁷University of Szeged Medical School, Szeged, HU
34
35
36
37
38
39
40

41 Key words: new-onset diabetes mellitus, pancreatic cancer, biomarker, screening
42
43

44 **Correspondence to:**

45 László Czakó, MD, PhD, DSc

46 First Department of Medicine,

47 University of Szeged,

48 Szeged, P.O.Box: 427, H-6701, Hungary

49 E-mail: czako.laszlo@med.u-szeged.hu

50 Telephone: +36-62-545187, Fax: +36-62-545185
51
52
53
54
55
56
57

58 Word count: 3728
59
60

ABSTRACT

Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with an overall 5-year survival of approximately 8%. The success in reducing the mortality rate of PDAC is related not only to the discovery of new therapeutic agents, but also to a significant extent to the development of early detection and prevention programs. Patients with new-onset diabetes mellitus represent a high-risk group for PDAC as they have an 8-fold higher risk of PDAC than the general population. The proposed screening program may allow the detection of PDAC in the early, operable stage. Diagnosing more patients in the curable stage might decrease the morbidity and mortality rates of PDAC and additionally reduce the burden of the healthcare.

Methods & Analysis: This is a prospective, multicentre observational cohort study. Patients ≥ 60 years old diagnosed with new-onset (≤ 6 months) diabetes will be included. Exclusion criteria are (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; (5) present malignant disease and (6) type-1 diabetes mellitus. Follow up visits are scheduled every 6 months for up to 36 months. Data collection is based on questionnaires. Clinical symptoms, body weight and fasting blood will be collected at each, CA 19-9 and blood to biobank at every second visit. The blood samples will be processed to plasma and analysed with mass spectrometry-based metabolomics. The metabolomic data will be used for biomarker validation for early detection of PDAC in the high-risk group new-onset diabetes patients. Patients with worrisome features will undergo MRI or EUS investigation, and surgical referral depending on the radiological findings. One of the secondary endpoints is the incidence of PDAC in patients with newly diagnosed diabetes mellitus.

Ethics and dissemination: the study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (41085-6/2019). We plan to disseminate the results to several members of the healthcare system including medical doctors, dietitians, nurses, patients etc. We plan to publish the results in a peer-reviewed high quality journal for professionals. In addition, we also plan to publish it for lay readers in order to maximize the dissemination and benefits of this trial.

Trial registration: The trial has been registered at the ClinicalTrials.gov (NCT04164602).

Strengths and limitations of this study:

Strength 1: As patients are included prospectively, the study will yield a cohort to examine the metabolic changes that coincide with the occurrence of PDAC at a very early stage before it is diagnosed.

Strength 2: The criteria for the diagnoses of diabetes and PDAC will be uniformly applied throughout the study period, moreover the diagnosis of pancreatic cancer will be confirmed with a high level of certainty in all subjects.

Strength 3: Taking part in the screening is connected to a very low burden, as the blood collection is only minimally invasive.

Strength 4: All patients will be monitored closely and frequently, which will increase the survival of all participants, especially the high-risk patients.

Limitation 1: It might be really difficult to include the required number of patients, considering that PDAC is a rare disease, and the elderly population has more comorbidities which not just makes our observations more difficult, but also leads to a higher follow-up loss during the 36 months.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is a rare disease with a lifetime prevalence of 1.39%, but its prevalence is continuously increasing (1-3). The prognosis is extremely poor: it has a five-year survival rate of only 7-8% (4), and this rate has barely improved in the last 40 years (5). PDAC will be the second leading cause of cancer-related death by 2030 (6). The high mortality rate is a consequence of delayed diagnosis: in the absence of specific symptoms, PDAC is often diagnosed at an advanced stage. Surgery is the only curative treatment at this moment. Unfortunately, only 20% of the patients are eligible for curative resection at the time of the diagnosis because of the presence of metastases and locoregional infiltration (7). The success in reducing the mortality rate of PDAC is related to a significant extent to the development of early detection and prevention programs. An effective screening programme is needed for the early diagnosis of PDAC in the asymptomatic stage to improve the prognosis. Due to the low lifetime prevalence, the population-based screening is neither feasible nor cost-effective. It is recommended that subjects at high risk of PDAC should be screened (8).

Pancreatic ductal adenocarcinoma and diabetes mellitus

Patients with diabetes mellitus (DM) have an eight-fold higher risk of developing PDAC within 2–3 years after the diagnosis of diabetes relative to the general population (9). In a meta-analysis which included 36

1
2
3 studies, individuals in whom DM had only recently been diagnosed (<4 years) had a 50% increased risk
4 of PDAC as compared with individuals who had diabetes for >5 years (10). Another meta-analysis of 35
5 cohort studies showed that DM was associated with an increased risk of PDAC (summary relative risks
6 (RRs)=1.94; 95% CI, 1.66–2.27). Interestingly, the risk decreased with the duration of diabetes (5.38 for
7 <1 year, 1.95 for 1–4 years, and 1.49 for 5–9 years, 1.47 for ≥ 10 years), thus providing evidence that
8 diabetes in PDAC patients is caused by the cancer itself (11). In these cases, patients are actually
9 suffering from diabetes type 3c (T3cDM). Diabetes is already prevalent in small PDACs (12), and what is
10 more important, that diabetes occurs before the tumour is radiologically detectable (13). A population-
11 based study found that approximately 1% of patients with new-onset diabetes at age 50 or older will be
12 diagnosed with PDAC within 3 years of first meeting criteria for diabetes, and 56% of these within 6
13 months of meeting the criteria for diabetes (9). Recognition of new-onset diabetes as an early
14 manifestation of PDAC could lead to diagnosis of asymptomatic, early-stage PDAC (14). In our recent
15 prospective study, the prevalence of PDAC in patients with new-onset diabetes was significantly higher
16 than in the general population (the value of the Standardised Incidence Ratio for PDAC in new-onset type
17 2 diabetic patients was 198.6 (95% CI = 6.25-46.9)); therefore, screening seems to be beneficial for
18 detecting PDAC in this patient population (15). Weight loss in patients with pancreatic carcinoma-
19 associated DM often precedes the onset of diabetes, while new-onset primary type 2 DM is typically
20 associated with weight gain (16). The paradoxical development of diabetes in the face of ongoing weight
21 loss may be an important clue to diagnose PDAC in patients with new onset of diabetes.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Screening modalities**

38
39
40
41 The carbohydrate antigen 19-9 (CA19-9) is currently the only blood-based biomarker in clinical use for
42 PDAC. The sensitivity of this marker for PDAC is 75%, the specificity is 90%, the positive predictive
43 value is 69%, and the negative predictive value is 90% (17). These values fall below the required
44 characteristics of a reliable screening test (10, 18); therefore, serum CA19-9 measurement is not suitable
45 for screening for PDAC. Imaging modalities represent the gold standard for diagnosing PDAC. The first
46 choice is transabdominal ultrasonography, however, its sensitivity in PDAC diagnosis is only 50–70%.
47 Its accuracy is low in tumours <1 cm, which are usually operable and negatively influenced by obesity
48 and meteorism (19). Computer tomography has a better accuracy in diagnosing PDAC; however, the low
49 prevalence of PDAC and radiation exposure associated with the modality prevents it from being used as a
50 screening test. The odds for a correct diagnosis are also high employing endoscopic ultrasound or
51 endoscopic retrograde cholangiopancreatography (ERCP), but again the low prevalence of PDAC in
52 combination with the burden of the endoscopic intervention to the patient preclude the application of
53
54
55
56
57
58
59
60

1
2
3 these diagnostic methods for screening. Furthermore, it is not economically feasible to employ computer
4 tomography or endoscopic imaging for screening as these methods are associated with high costs to the
5 healthcare system.
6
7

8 The success of the strategy of using new-onset diabetes as a screening tool to identify subjects with a high
9 likelihood of having asymptomatic PDAC will depend on our ability to differentiate PDAC-associated
10 diabetes from the more common type 2 diabetes. PDAC-induced diabetes is thought to be a
11 paraneoplastic phenomenon involving the release of products from the tumour rather than a result of the
12 destruction of the pancreas due to malignant infiltration (20, 21). Data on incidence of PDAC in new
13 onset DM is rare, numbers of 0.25% (22), 0.85% (9), and 3.6% (23) have been reported. Therefore, to
14 enable a diagnostic follow-up of new onset of diabetes, a further enrichment of this group is needed (14,
15 24, 25), e.g. elderly subjects (age is an independent risk factor for PDAC), weight loss (26), or smoking.

16 A biomarker panel consisting of nine metabolites plus the established protein CA19-9 were recently
17 identified by Mayerle and colleagues with 89.9% sensitivity, 91.3% specificity and 99.8% negative
18 predictive value for differentiating PDAC from chronic pancreatitis (27). Employing the same methods, a
19 biomarker panel for differential diagnosis between PDAC and non-cancer-related diabetes was identified.
20 The metabolite signature needs validation in an independent test cohort, which will be enabled with the
21 present study. Provided the biomarker is validated, the panel could be effective for screening of the high-
22 risk group patients diagnosed with new-onset DM.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Aims of the project**

- 39
40
41 a) Estimate the incidence of pancreatic ductal adenocarcinoma in patients with new-onset diabetes
42
43 b) Diagnose pancreatic ductal adenocarcinoma in an early operable stage
44
45 c) Validate a biomarker that distinguishes patients with PDAC-caused T3cDM from patients with
46 T2DM.
47
48
49

50 **METHODS AND ANALYSIS**

51 **Design**

52
53 This is a prospective, multicentre, observational cohort study aiming to validate a biomarker panel in the
54 early stage of PDAC. The data collection is based on questionnaires and blood samples will be drawn
55 from all patients. The questionnaires (Form A at recruitment, Form B at every follow up visit) will be
56 filled by every included patients.
57
58
59
60

Table 1. Diagnostic criteria of diabetes mellitus.

The inclusion criteria of this study are the following: (1) patients over 60 years of age; (2) diabetes

Parameter	Value and unit	Description
Fasting plasma glucose	≥ 126 mg/dL (7.0 mmol/L)	Fasting is defined as no caloric intake for at least 8 h.
2 h plasma glucose	≥ 200 mg/dL (11.1 mmol/L)	Oral glucose tolerance test. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
HbA1c	$\geq 6.5\%$ (48 mmol/mol)	The test should be performed in a laboratory using a method that is NGSP certified and standardised to the DCCT assay.

diagnosed within six months (newly diagnosed) - diagnostic criteria are based on the Diabetes Control and Complications Trial (Table 1. (28)); (3) signed written informed consent.

Exclusion criteria are as follows: (1) continuous alcohol abuse; (2) chronic pancreatitis; (3) previous pancreas operation/pancreatectomy; (4) pregnancy; (5) present malignant disease; and (6) type-1 diabetes mellitus. Patients with chronic pancreatitis were excluded because a metabolic signature differentiating between chronic pancreatitis and PDAC patients has already been published (27) and is currently further evaluated by the META-PAC consortium, while the present study aims to differentiate between patients with PDAC-caused new onset diabetes and new onset diabetes due to other causes.

Sample size

Mayerle et al. found that the biomarker signature in question could distinguish patients with PDAC from those without with an 89.9% sensitivity (marginal error 8.9%) and 81.3% specificity (marginal error 10.3%)(27). Chari et al. concluded that elderly subjects with new-onset DM has 8 times higher risk for pancreatic cancer than for a person of similar age and sex without DM (9). In the light of the epidemiologic data suggest that in Hungary the prevalence of PDAC is considerably higher than that compared to other countries` (29), we assumed a 2% prevalence for PDAC. In reference to these data, sample size calculation suggests that 2661 patients will need to be enrolled in order to confirm or reject the hypothesis for the primary endpoint with a 10% dropout, 80% power and 95% significance level. The recruitment period is planned to last 36 months, and all included patients will be followed for 36 months.

Duration:

The first recruiting centre will be initialized in 1 July 2019. Start of the patient recruitment: January 31, 2020. Planned finish of the study-recruitment: January 30, 2023.

Clinical data and clinical endpoints:

1
2
3 Essential baseline clinical data: age, sex, body weight, BMI, date of DM diagnosis, date of sampling,
4 comorbidities, antidiabetic medication, clinical symptoms, histology and stage of PDAC.
5
6
7

8 Primary clinical endpoints: the sensitivity, specificity, positive and negative predictive values, and
9 accuracy of the biomarker test.
10

11 Secondary endpoints:

12 (1) mortality of pancreatic ductal adenocarcinoma in new-onset diabetic patients; (2) the proportion of
13 localised and resectable pancreatic ductal adenocarcinoma; (3) change in body weight before Visit 1 and
14 during Visit 2-6; (4) change in fasting blood glucose and HbA1c before Visit 1 and during Visit 2-6; (5)
15 antidiabetic medications and the risk of pancreatic ductal adenocarcinoma; (6) presence of concomitant
16 diseases; (7) smoking and alcohol intake; (8) incidence of pancreatic ductal adenocarcinoma in patients
17 with new-onset diabetes; (9) cost-benefit analysis.
18
19
20
21
22
23
24
25

26 **Study protocol:**

27 Diabetic patients will be recruited by our diabetologist and collaborating family physicians based on a
28 recent (< 6 months) laboratory test (Table 1). Visit 0 is scheduled within 2 weeks from the referral
29 (Figure 1). Patients who meet study entry criteria and no exclusion, will be informed and offered to
30 participate in the study, however signed informed consent will be necessary for inclusion. Clinical data,
31 body weight and worrisome features (unintentional weight loss: 5% of body weight within 6 months
32 without knowing the reason (30), abdominal pain/discomfort, abnormal laboratory data, unstable glucose
33 metabolism despite the adequate diet and medical treatment and without intercurrent infection) will be
34 recorded at Visit 0, and a fasting blood sample will be taken for assessment of laboratory data and
35 metabolomics. C-peptide and glutamic acid decarboxylase antibodies (GADA) will be determined to
36 classify diabetes at Visit 0. Patients with type-1 diabetes mellitus will be excluded. If worrisome features
37 are present at Visit 0, MRI or EUS is performed. Unambiguous PaC lesions (>1 cm or seen also by
38 magnetic resonance imaging) will be referred to surgery for resection. In case of ambiguous lesions in the
39 pancreas, EUS-fine needle aspiration will be performed. Visit 1-5 are scheduled every 6 months. Clinical
40 symptoms, body weight, laboratory data (fasting blood glucose, HbA1c, liver and renal function, lipids,
41 blood count) will be collected at each visit. Blood to biobank and CA 19-9 will be taken at every 12
42 months. The follow-up will be closed at 36 months.
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **Biochemical methods**

57 After informed consent, fasted (overnight, at least 8 h) patients' blood samples will be drawn into an
58 EDTA tube. 9 ml blood tubes are centrifuged within 2 h after blood draw using a swing-out rotor at
59
60

1
2
3 2000 xg for 10 minutes. The sample processing is done at room temperature and the centrifuge is
4 temperature-controlled at 19-21°C. After centrifugation, the supernatant is carefully removed, transferred
5 to a fresh 9 ml tube and gently mixed in order to homogenise any gradient that might have been generated
6 in the plasma supernatant. After that, the plasma is transferred in 0.5 ml aliquots to tubes (either
7 Eppendorf Safe-Lock-Tubes 2 ml or Sarstedt Screw cap micro tubes 2 ml) and stored at -80°C, in a
8 dedicated freezer (≤ 6 h from centrifuge to freezer). Biomarkers will be determined comparing metabolite
9 levels in plasma samples from patients diagnosed with PDAC and diabetic cancer-free patients (26).
10 CA19-9 determination is performed centralised at a certified clinical laboratory applying a cut-off of
11 37 U/ml as a classifier.

12
13
14
15
16
17
18
19 Cost of the biomarker test, quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio
20 (ICER) will be determined.
21
22

23 24 **Metabolite profiling:**

25 **MxP® Global Profiling:**

26
27 Two types of mass spectrometry analyses are applied. GC-MS (gas chromatography-mass spectrometry;
28 Agilent 6890 GC coupled to an Agilent 5973 MS System, Agilent, Waldbronn, Germany) and LC-
29 MS/MS (liquid chromatography-MS/MS; Agilent 1100 HPLC-System, Agilent, Waldbronn, Germany,
30 coupled to an Applied Biosystems API4000 MS/MS-System, Applied Biosystems, Darmstadt, Germany)
31 are used for a metabolite profiling approach (31). Fractionation and derivatisation of samples and
32 detection technologies have been previously described (32-35). Proteins are removed from plasma
33 samples (60 μ l) by precipitation. Subsequently, polar and non-polar fractions are separated for both GC-
34 MS and LC-MS/MS analyses by adding water and a mixture of ethanol and dichloromethane. For GC-
35 MS analyses, the non-polar fraction is treated with methanol under acidic conditions to yield the fatty acid
36 methyl esters derived from both free fatty acids and hydrolysed complex lipids. The polar and non-polar
37 fractions are further derivatised with O-methyl-hydroxylamine hydrochloride (20 mg/ml in pyridine) to
38 convert oxo-groups to O-methyloximes and subsequently with a silylating agent (N-Methyl-N-
39 (trimethylsilyl) trifluoroacetamide) before GC-MS analysis. For LC-MS/MS analyses, both fractions are
40 dried and subsequently reconstituted in appropriate solvent mixtures. HPLC (High performance LC) is
41 performed by gradient elution using methanol/water/formic acid on reversed phase separation columns.
42
43
44
45
46
47
48
49
50
51
52
53

54 **MxP® Lipids:**

55
56 MxP® Lipids covers profiling of sphingolipids (ceramides, sphingomyelins, and sphingobases). The
57 metabolites are analysed in a semi-quantitative approach (i.e. relative to a pool). Total lipids are extracted
58 from plasma by liquid/liquid extraction using chloroform/methanol. The lipid extracts are subsequently
59
60

1
2
3 fractionated by normal phase liquid chromatography (NPLC) into different lipid groups according to (32,
4 36). The fractions are analysed by LC-MS/MS using electrospray ionization (ESI) and atmospheric
5 pressure chemical ionization (APCI) with detection of specific multiple reaction monitoring (MRM)
6 transitions for sphingomyelins (SM) and ceramides (CER) respectively.
7
8
9

10 11 **Data normalization**

12
13 Details of data normalization have been published (27). Metabolite profiling based on a semi-quantitative
14 analytical platform results in relative metabolite levels (“ratio”) to a defined reference. To support this
15 concept and to allow an alignment of different analytical batches, two different reference sample types are
16 run in parallel throughout the whole process. First, a project pool is generated from aliquots of all samples
17 and measured with four replicates within each analytical sequence that comprised 24 samples. For all
18 semi-quantitatively analysed metabolites, the results of each analyte from each sample are normalised
19 against the median of the corresponding analyte in the pool reference samples within each analytical
20 sequence to provide pool-normalised ratios. This process step compensates for inter- and intra-
21 instrumental variation, i.e. variability that occurs when different analytical sequences are analysed by
22 different devices. Second, to allow for an experiment-to-experiment alignment of semi-quantitative data,
23 MxPool™ (a large pool of a commercial human EDTA plasma suited for alignment of MxP® studies) is
24 analysed with 12 replicated samples, and the pool-normalised ratios are further normalised to the median
25 of the MxPool™ samples, i.e. ratios from this study are on the same level and therefore comparable with
26 data from other studies normalised to other aliquots of the same MxPool™. A rigorous quality control is
27 performed on peak, analyte and sample level and has been described previously (37).
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Data collection and follow-up**

42
43 Data collection is based on questionnaires, and will be stored in a personalised electronic database
44 (eCRF). Form A: contains all antropometric parameters, routine clinical chemistry tests, fasting blood
45 glucose and HbA1c. Follow-up visits will be scheduled by the patient registration system every 6 months.
46 Blood will be taken for biomarker identification with metabolomics and CA19-9 determination at every
47 12 months. The total follow-up period is three years.

48
49
50
51 Pancreas adenocarcinoma will be diagnosed by histological examination.
52
53
54

55 **Data set analysis and normalization**

56
57 Descriptive statistics – mean, median, standard deviation, quartiles and relative frequency –relative risk
58 (dichotomous variables), Independent Two-sample T test (continuous variable) in the case of normal
59 distribution, furthermore Mann-Whitney test in lack of normal distribution will be performed. Logistic
60

1
2
3 regression will be applied for the exploring of predictive factors. Affiliated statistical analyses will be
4 performed with an error probability of 0.05 (type-I error probability).
5

6 Prior to statistical analysis, log₁₀ transformation of ratios is conducted so that the data distribution
7 becomes approximately normal. SIMCA-P version 14.0 (Umetrics AB, Umea, Sweden), TIBCO®
8 Spotfire® 7.12.0 and R 3.3.4 are used for data analyses and visualizations. Initially, an exploratory
9 multivariate analysis (Principal Component Analysis, PCA) is applied to log₁₀-transformed ratios scaled
10 to unit variance.
11
12
13
14

15 A simple linear model (ANOVA, package nlme) addressing additional clinical information and
16 potentially confounding factors such as “disease”, “age”, “body mass index”, “gender” and “sample
17 storage time” as fixed effects is fitted to the data. Significance level is set to 5%. The multiple test
18 problem for the number of metabolites is addressed by calculating the false discovery rate (FDR) using
19 the Benjamini & Hochberg method (38).
20
21
22
23

24 To classify patients depending on their metabolic profiles a penalised logistic regression is fitted via
25 Elastic Net Algorithm using the R package glmnet (38). Equal penalties are used for both the L1 and the
26 L2 norm. Afterwards the cutoff established previously on the biomarker identification dataset is applied
27 on the test data without retraining, and the performance is measured in terms of area under the curve
28 (AUC), sensitivity and specificity. Confidence levels for the AUC are calculated using the binormal
29 model for the receiver operating characteristic (ROC) curve. When the sensitivity is fixed at a particular
30 value, the positive and negative predictive values (PPV, NPV) and the accuracy become monotone
31 functions of the specificity; and confidence intervals for these estimates are obtained by transformation of
32 the confidence interval for the specificity. Confidence intervals for sensitivity, specificity and accuracy
33 are obtained for the cutoff pre-specified in the training data by the method of Clopper and Pearson for the
34 binomial distribution. For PPV and NPV the confidence intervals will be obtained by the method of Gart
35 and Nam (39) for ratios of binomial parameters as implemented in the R package pairwise CI (40). When
36 comparing the biomarker and CA19-9 on the test data, differences in sensitivity and specificity will be
37 tested for with the McNemar test.
38
39
40
41
42
43
44
45
46
47
48
49

50 **Centres**

51 The study will start with the following centres (University of Szeged, University of Pécs, University of
52 Semmelweis), however, other centres are welcome to participate as an open label study. Completion of
53 the LETTER OF INTENT form will be mandatory for registering the participation of each institution.
54
55
56
57

58 **PATIENT AND PUBLIC INVOLVEMENT**

59 No patients involved.
60

ETHICS AND DISSEMINATION

Trial registration: The trial has been registered at the ClinicalTrials.gov (NCT04164602)

Ethical approval: the study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (41085-6/2019). Protocol Version: V1.0 08.01.2019.

Publication policy

Centres providing more than 50 patients can provide author to the authorship list.

Dissemination policy

We plan to disseminate the results to several members of the healthcare system including medical doctors, dietitians, nurses, patients etc. We plan to publish the results in a peer-reviewed high quality journal for professionals. In addition, we also plan to publish it for lay readers in order to maximize the dissemination and benefits of this trial.

DISCUSSION

PDAC has a dismal prognosis, which is due to its late diagnosis. The success in reducing the mortality rate of PDAC is related to the development of early detection and prevention programs. Age and DM are known as risk factors of PDAC (9-11, 14, 15).

The expected positive endpoint of this study is to validate a biomarker panel in elderly patients diagnosed with diabetes; whether it is suitable for early stage diagnosis of a mostly incurable, high-mortality cancer, when surgery is still possible and the cancer can be cured. PDAC-induced diabetes belongs to the group T3cDM and in parallel, T3cDM means the highest-high risk group for PDAC. Unfortunately, it is still underdiagnosed in the clinical practice – maybe because its symptoms are very similar to T2DM's and its diagnosis is based on complex, expensive tests that are not routinely available (41). To diagnose T3cDM patients based on these criteria would lead to enormous difficulties and it would not be a cost-effective screening method, which is unfavorable. While there are several pancreatic diseases that can cause T3cDM, this study focuses on the differences between PDAC-T3cDM and T2DM only. In that manner, this biomarker panel could be a diagnostic tool for the T3cDM-subgroup PDAC-T3cDM. The test only requires one blood sample collection, which means that it is simple, repeatable, tolerable, minimally invasive, nearly painless, widely achievable and relatively cheap – it fulfils all the criteria set for a screening method. Identifying PDAC in an earlier (still resectable) stage through surveillance of high-risk patients would increase surgical resection rate, cure rates and survival by 30–40%. It would save lives, maintain better well-being among the population and would have an enormous financial benefit: the increasing number of successful surgical interventions leads to a lower necessity of chemotherapy and

1
2
3 palliative interventions (such as stent implantations or gastroenteroanastomosis operations), moreover
4 lower the burden the healthcare cost.
5
6
7

8 **Trial organization, committees and boards:** The coordinator of the NODES study is LC with the
9 support of the Hungarian Pancreatic Study Group (HPSG-coordinating society, [https://tm-](https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/)
10 [centre.org/en/study-groups/hungarian-pancreatic-study-group/](https://tm-centre.org/en/study-groups/hungarian-pancreatic-study-group/)). HPSG has been running high-quality
11 international, multicentre clinical trials since 2014 and has published the relevant guidelines for
12 pancreatic diseases to improve patient care in pancreatology (42-50).
13
14
15
16

17 The trial will be supported by the following committees:
18

19
20 Steering Committee (SC): This committee will be led by PH (gastroenterologist and internal medicine
21 specialist). The members in Szeged (HU) will be: DI, EI.
22
23
24

25 International Translational Advisory Board (ITAB): This board will involve gastroenterologists. The
26 ITAB will regularly monitor the progression of the trial and might give recommendations to the SC.
27
28
29

30 Data Monitoring Committee (DMC): DMC will handle all the data and ensure that the data in the eCRF is
31 accurate, complete and legible. Data Management Plan (DMP) will describe the detailed data flow. The
32 Data Manager will validate the data from completed eCRFs, according to a Data Cleaning Plan (DCP).
33 Any missing, implausible or inconsistent recordings in the eCRFs will be referred back to the Investigator
34 using a data query form (DQF), and be documented for each individual subject before clean file status is
35 declared. All changes to eCRFs will be recorded.
36
37
38
39
40

41 ACKNOWLEDGEMENTS

42 **Funding**

43
44 The study was supported by National Research, Development and Innovation Office grants (K128222 to
45 LC). Center costs (IT, biostatistics, trial organization, etc) are covered by the University of Pécs Medical
46 School, Momentum Grant of the Hungarian Academy of Sciences (LP2014-10/2014); and Economic
47 Development and Innovation Operative Programme Grant and Highly Cited Publication Grant of the
48 National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00048 Stay Alive, KH-
49 125678 and EFOP 3.6.2-16-2017-00006 Live Longer).
50
51
52
53
54

55 **Authors' contributions**

56
57 The study was designed by ID, LC, BK. ID, LC, MGA drafted the manuscript. All authors edited, read
58 and approved the final manuscript. Literature search, statistical calculation and figures preparation will be
59
60

1
2
3 done by SV, NZ, AS, BC, KM. Steering Committee will be led by PH. During the study ID, EI, GH, KK,
4 IO, GZ, MT, MS, VH, LC are going to collect the patients.
5
6

7 **CONFLICT OF INTEREST STATEMENT**

8

9 BK and MGA are employees of Metanomics Health GmbH, Germany.
10
11

12 The other authors have no competing interest.
13
14
15

16 **Abbreviations:**

17 APCI - atmospheric pressure chemical ionization

18 AUC – area under the curve

19 CA 19-9 – carbohydrate antigen 19-9

20 CER – ceramides

21 DM – diabetes mellitus

22 DMC - Data Monitoring Committee

23 ERCP – endoscopic retrograde cholangio-pancreatography

24 ESI - electrospray ionization

25 EUS – endoscopic ultrasound

26 FDR - false discovery rate

27 GC-MS - gas chromatography-mass spectrometry

28 HbA1c – haemoglobin A1c

29 HPSG – Hungarian Pancreatic Study Group

30 ITAB - International Translational Advisory Board

31 LC- MS/MS - liquid chromatography-MS/MS

32 MRI – magnetic resonance imaging

33 MRM - multiple reaction monitoring

34 NPLC - normal phase liquid chromatography

35 NPV – negative predictive value

36 PaC – pancreatic cancer

37 PCA - principal component analysis

38 PPV – positive predictive value

39 ROC - receiver operating characteristic

40 SC - Steering Committee

41 SM – sphingomyelins
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 SP –Sponsor

4 T2DM – type 2 diabetes mellitus

5
6 T3cDM – type 3c diabetes mellitus
7
8
9

10 REFERENCES


11
12

- 13 1. National Cancer Institute. SEER Cancer Statistics Review 1975-2006.
- 14 2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the
15 world. *HPB (Oxford)* 2008;10:58-62.
- 16 3. Malvezzi M, Bertuccio P, Levi F et al. European cancer mortality predictions for the year 2013. *Ann*
17 *Oncol* 2013;24:792-800.
- 18 4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7–30.
- 19 5. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and
20 Risk Factors. *World J Oncol.* 2019;10(1):10-27.
- 21 6. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the
22 unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res*
23 2014;74:2913-21.
- 24 7. Gillen S, Schuster T, Meyer ZBC, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a
25 systematic review and meta-analysis of response and resection percentages. *PLoS Med* 2010;7(4):
26 e1000267.
- 27 8. Brand RE, Lerch MM, Rubinstein WS et al. Advances in counselling and surveillance patients at risk
28 for pancreatic cancer. *Gut* 2007;56:1460-9.
- 29 9. Chari ST, Leibson CL, de Andrade M, et al. Probability of pancreatic cancer following diabetes:
30 population-based study. *Gastroenterology* 2005;129:504-511.
- 31 10. Huxley R, Ansary-Moghaddam A, Berrington de González A et al. Type-II
32 diabetes and pancreatic cancer: a meta-analysis of 36 studies. *Br J Cancer* 2005;92(11):2076-83.
- 33 11. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort
34 studies. *Eur. J. Cancer* 2011;47:1928-1937.
- 35 12. Tsuchiya R, Noda T, Harada N et al. Collective review of small carcinomas of the pancreas. *Ann*
36 *Surg* 1986;203:77-81.
- 37 13. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic
38 cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting
39 glucose values prior to diagnosis. *Am J Gastroenterol* 2007;102:2157-2163.
- 40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

14. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. *Lancet Oncol* 2009;10:88-95.
15. Illés D, Terzin V, Holzinger G et al. New-onset type 2 diabetes mellitus--A high-risk group suitable for the screening of pancreatic cancer? *Pancreatology* 2016;16(2):266-71.
16. Hart PA, Kamada P, Rabe KG et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. *Pancreas* 2011;40(5):768-72.
17. Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. *J Gastroenterol Hepatol* 2004;19(2):182-6.
18. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. *Inhal Toxicol* 2014;26(13):811-28.
19. Rickes S, Unkrodt K, Neye H et al. Differentiation of pancreatic tumours by conventional ultrasound, unenhanced and echoenhanced power Doppler sonography. *Scand J Gastroenterol* 2002;37:1313-20.
20. Pannala R, Leirness JB, Bamlet WR et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. *Gastroenterology* 2008;134:981-987.
21. Aggarwal G, Ramachandran V, Javeed N et al. Adrenomedullin up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. *Gastroenterology* 2012;143:1510-1517.
22. Munigala S, Singh A, Gelrud A et al. Predictors for Pancreatic Cancer Diagnosis Following New-Onset Diabetes Mellitus. *Clin Transl Gastroenterol* 2015;6:e118.
23. Choe JW, Kim JS, Kim HJ et al. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. *Pancreas* 2016;45:730-4.
24. Muniraj T, Chari ST. Diabetes and pancreatic cancer. *Minerva gastroenterologica e dietologica* 2012;58:331-45.
25. Chari ST, Kelly K, Hollingsworth MA et al. Early detection of sporadic pancreatic cancer: summative review. *Pancreas* 2015;44:693-712.
26. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. *Nat Rev Gastroenterol Hepatol* 2013;10:423-33.
27. Mayerle J, Kalthoff H, Reszka R, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. *Gut* 2018;67(1):128-137.
28. American Diabetes Association: Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. *Diabetes Care* 2018; 41(Supplement 1): S13-S27.
29. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J Oncol*. 2019;10(1):10-27

- 1
- 2
- 3 30. Rabinovitz M, Pitlik SD, Leifer M et al. Unintentional weight loss. A retrospective analysis of 154
- 4 cases. *Arch Intern Med* 1986;146(1):186-7.
- 5
- 6 31. Jung K, Reszka R, Kamlage B et al. Tissue metabolite profiling identifies differentiating and
- 7 prognostic biomarkers for prostate carcinoma. *Int J Cancer* 2013;133:2914–2924.
- 8
- 9 32. Christie WW. Rapid separation and quantification of lipid classes by high performance liquid
- 10 chromatography and mass (light-scattering) detection. *J Lipid Res* 1985;26:507-12.
- 11
- 12 33. Mutch DM, Fuhrmann JC, Rein D et al. Metabolite Profiling Identifies Candidate Markers Reflecting
- 13 the Clinical Adaptations Associated with Roux-en-Y Gastric Bypass Surgery. *Plos One*
- 14 2009;4(11):e7905.
- 15
- 16 34. Roessner U, Wagner C, Kopka J et al. Technical advance: simultaneous analysis of metabolites in
- 17 potato tuber by gas chromatography-mass spectrometry. *Plant J* 2000;23:131-42.
- 18
- 19 35. van Ravenzwaay B, Cunha GCP, Leibold E et al. The use of metabolomics for the discovery of new
- 20 biomarkers of effect. *Toxicology Letters* 2007;172:21-8.
- 21
- 22 36. Schmidt H, Schmidt R, Geisslinger G. LC-MS/MS-analysis of sphingosine-1-phosphate and related
- 23 compounds in plasma samples. *Prostaglandins & Other Lipid Mediators* 2006;81:162-70.
- 24
- 25 37. Meller S, Meyer HA, Bethan B et al. Integration of tissue metabolomics, transcriptomics and
- 26 immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate
- 27 cancer. *Oncotarget* 2016;7:1421-38.
- 28
- 29 38. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - A Practical and Powerful
- 30 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological*
- 31 1995;57:289-300.
- 32
- 33 39. Gart JJ, Nam J. Approximate interval estimation of the ratio of binomial parameters: a review and
- 34 corrections for skewness. *Biometrics* 1988;44:323-38.
- 35
- 36 40. Scherer R, Schaarschmidt F, Prescher S, Priesnitz KU. Simultaneous confidence intervals for
- 37 comparing biodiversity indices estimated from overdispersed count data. *Biometrical Journal*
- 38 2013;55:246-63.
- 39
- 40 41. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (type 3c)—are we neglecting
- 41 an important disease? *Eur J Intern Med* 2013;24:203–206.
- 42
- 43 42. Hritz I, Hegyi P. Early Achievable Severity (EASY) index for simple and accurate expedite risk
- 44 stratification in acute pancreatitis. *J Gastrointest Liver Dis* 2015;24(2):177–82.
- 45
- 46 43. Párniczky A, Mosztbacher D, Zsoldos F et al. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-
- 47 study protocol of a multinational prospective clinical trial. *Digestion* 2016;93(2):105–10.
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3 44. Zsoldos F, Párniczky A, Mosztbacher D, et al. Pain in the Early Phase of Pediatric Pancreatitis
- 4 (PINEAPPLE Trial): Pre-study protocol of a multinational prospective clinical trial. *Digestion*
- 5 2016;93(2):121–6.
- 6
- 7
- 8 45. Dubravcsik Z, , Madácsy L, Gyökeres T, et al. Preventive pancreatic stents in the management of
- 9 acute biliary pancreatitis (PREPAST trial): pre-study protocol for a multicenter, prospective,
- 10 randomized, interventional, controlled trial. *Pancreatology* 2015;15(2):115–23.
- 11
- 12 46. Márta K, Szabó AN, Pécsi D, et al. High versus low energy administration in the early phase of acute
- 13 pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. *BMJ*
- 14 *Open* 2017;7(9):e015874.
- 15
- 16 47. Dubravcsik Z, Farkas G, Hegyi P, et al. [Autoimmune pancreatitis. Evidence-based management
- 17 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):292–
- 18 307.
- 19
- 20 48. Hritz I, Czakó L, Dubravcsik Z, et al. [Acute pancreatitis. Evidence-based practice guidelines
- 21 prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):244–61.
- 22
- 23 49. Párniczky A, Czakó L, Dubravcsik Zs, et al. [Pediatric pancreatitis. Evidence-based management
- 24 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(8):308–25.
- 25
- 26 50. Takács T, Czakó L, Dubravcsik Z, et al. [Chronic pancreatitis. Evidence-based management
- 27 guidelines prepared by the Hungarian Pancreatic Study Group]. *Orvosi Hetilap* 2015;156(7):262–88.
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1. Flowchart of the study protocol

* weight loss (except at visit0), abdominal pain/discomfort, abnormal laboratory data, unstable glucose metabolism despite the adequate diet and medical treatment and without intercurrent infection (except at visit0)
EUS: endoscopic ultrasound; MRI: magnetic resonance imaging

** Fasted (overnight, at least 8 h) patients' blood samples at room temperature will be drawn into an EDTA tube. Within 2 h after blood draw samples will be at 19-21°C. After centrifugation, the supernatant is carefully removed. After that, the plasma is transferred in 0.5 ml aliquots to tubes and stored at -80°C, in a dedicated freezer (≤6 h from centrifuge to freezer).